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ABSTRACT
Trabectedin (ET-743, Yondelis) is a marine alkaloid isolated from the tunicate 
Ecteinascidia turbinata, cytotoxic against a variety of tumor cell lines in vitro and human 
tumor xenografts in vivo. It has been approved by EMEA for the 2nd line therapy of soft
j
tissue sarcomas in 2007 and for the 2 line therapy of ovarian cancer in 2009. Myxoid
liposarcoma (ML) is a specific histological subtype within the family of adults soft tissue
sarcomas. Specifically >90% of usual myxoid/round cell liposarcomas (ML/RCLS) are
characterized by the chromosomal translocation t(12;16) (ql3; p l l ) ,  which produces the
FUS-CHOP oncogene. Different chimera subtypes seem to respond differently to
trabectedin in clinical setting. To elucidate the mechanisms behind the differential
sensitivity to trabectedin, tumor myxoid liposarcomas type II and type III were xenografted
I
in nude mice, treated with trabectedin (0.15 mg/kg was injected i.v.) and the binding of 
FUS-CHOP to some of its target promoters was monitored by Chromatin immuno 
precipitation to verify the drug ability to displace the binding.We found that trabectedin 
was more effective on type II than type III ML xenografts. The response to trabectedin in 
Type II xenografts was associated with partial regression and pathological response. Type 
III ML xenografts appeared much less sensitive to trabectedin and tumors did not regress. 
Molecular analysis revealed that trabectedin was able to remove FUS-CHOP type II and III 
from its own gene targets 24 hours after treatment. 72 hours after treatment, FUS-CHOP 
Type III was attached to its targets whereas FUS-CHOP Type II remained unbound. The 
results suggest that the different of type II and type III to trabectedin are related to a 
different duration of the drug ability to display FUS-CHOP from DNA.
II
“Considerate la vostra semenza:
Fatti non foste per viver come bruti ma per seguir virtute e
canoscenza”
La Divina Commedia, Infemo/Canto XXVI - w . 118-120; Dante Alighieri
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Chapter 1:
INTRODUCTION
i
Sarcomas are a heterogeneous group of rare solid tumours of mesenchymal cell origin 
with distinct clinical and pathological features, and are divided into major categories: 
sarcoma of tissue (including fat, muscle, nerve and nerve sheath, blood vessels, and 
other connective tissues) and sarcomas of bone [1].
1.1 Soft tissue sarcomas (STS)
Soft tissue sarcomas (STS) are the most frequent type of sarcomas; the annual incidence 
in Itay for 2 011 was approximately 3000 cases per year [2].
In the last two decades our knowledge about the molecular pathogenesis of these 
tumours has increased dramatically, whereas little progress has been made on the 
therapy with the exception of the gastrointestinal sarcoma (GIST) driven by activating 
mutations of the proto-oncogene KIT, and thus sensitive to Imatinib [3], [4].
The most common primary sites are head and neck (9%), torso (18%), upper extremity 
(13%), retroparitoneum (13%), thigh, buttock and groin (46%). The anatomic site of the 
primary disease is important for treatment and for outcome (figure 1). STS metastasize 
to the lungs and others; tumours arising in the abdominal cavity usually metastasize to 
the liver and peritoneum [3].
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Common Sites of Soft Tissue Sarcomas
Torso 18%
Upper extremity 13%
Retroperitoneum 13%
Thigh, buttock, and groin 46%
Figure 1: com m on sites o f  Soft Tissue Sarcom a (m odified from http://w w w .m edscape.org/view article/572 942 )
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Figure 2: histological classification (m odified from http://w w w .m edscape.org/view article/572 942 )
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In recent years, molecular genetic testing has been useful to segregate sarcomas into 
two major genetic group: (a) sarcomas with specific genetic alterations and simple 
karyotypes including fusion genes due to reciprocal translocations (e.g. FUS-CHOP 
in myxoid liposarcomas) and specific mutations (e.g., KIT mutations in GISTs); and 
(b) sarcomas with nonspecific genetic alterations and complex unbalanced 
karyotypes, reflected by numerous genetic losses and/or gains [3, 4]. Chromosomal 
translocations are the majority of specific genetic alterations associated with 
sarcomas. Most of the chromosomal translocations have been cloned, and most of 
the fusion genes have been identified (Table 1). These fusion genes encode chimeric 
proteins that are important for the biology of the tumours, behaving in most cases as 
transcription factors that alter the transcription of multiple downstream genes and 
pathways. The resulting oncoproteins can provide useful diagnostic and prognostic 
information.
Soft tissue sarcomas (STS) with complex genomic profiles (50% of all STS) are 
predominantly composed of spindle cell/pleomorphic sarcomas, including 
leiomyosarcoma, myxofibrosarcoma, pleomorphic liposarcoma, pleomorphic 
rhabdomyosarcoma, malignant peripheral nerve sheath tumour, angiosarcoma, 
extraskeletal osteosarcoma, and spindle cell/pleomorphic unclassified sarcoma 
(previously called spindle cell/pleomorphic malignant fibrous histiocytoma). These 
neoplasms show, characteristically, gains and losses of numerous chromosomes or 
chromosome regions, as well as amplifications. Many of them share recurrent 
aberrations (e.g., gain of 5pl3-pl5) that seem to play a significant role in tumour 
progression and/or metastatic dissemination [3,4].
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TUMOR ABERRATION GENES INVOLVED
Alvootar soft part sarcoma der(17)(X;17){p11;q25) ASPL-TFE3
AngiomatokJ fibrous histiocytoma t(2;22)(q33.q12)
t(12;16)(q13;p11)
EWS-CREB1
TLS-AW1
Clear cell sarcoma t{12;22)(q13;q12)
t(2,22)(q33,q!2)
EWS-ATFI
EWS-CREB1
Congenitat/infantiie -  fibrosarcoma t(12;15)(p13;q25) ETV6W RK3
Dermatofibrosarcoma protuberans t(17;22)(q22;q13) and derivative 
ring chromosomes
COUAbPDGFB
Desmoid fibromatosis Trisomy 8 or 20; loss of 5q CTWNflf or APC mutations
Epithelioid sarcoma (proximal type) Bi-allelic inactivation of 22q11.2 INI1
Extrarenai rhabdoid tumor Bi-allelic inactivation of 22q11.2 INI1
Extraskeletal myxoid chondrosarcoma Rearrangements of 9q22 m
Sporadic GIST
Familial GIST (Camey-Stratakis syndrome)
Activating kinase mutations 
KREBS cycle mutation
KIT or POGFRA 
$0H  subunit mutations
Inflammatory myofibroblastic tumor Rearrangements of 2p23 ALK
Leiomyosarcoma Complex alterations Unknown
low-grade fibromyxoid sarcoma t(7;16)(q34;p11) TLSSBF2H7
Malignant peripheral nerve sheath tumor Complex alterations Unknown
Synovial sarcoma t(X;18)(pt1;q11)
t(X;18)(p11;q11)
SYT-SSX1
SYT-SSX2
Tenosynovial giant cell tumor/pigmented 
viilonodular synovitis (TGCT/PVNS)
t(1;2){p13;q35) CSF1
T a b le  1: Morphologic diagnosis based on microscopic examination o f  histologic sections remains the gold standard for sarcoma
diagnosis. However, several ancillary techniques are useful in support o f  morphologic diagnosis, including immunohistochemistry, 
classical cytogenetics, and molecular genetic testing. Molecular genetic testing has emerged as a particularly powerful ancillary 
testing approach because many sarcoma types harbor characteristic genetic aberrations, including single base-pair substitutions, 
deletions and amplifications, and translocations. Most molecular testing uses fluorescence in situ hybridization (FISH) approaches 
or polymerase chain reaction (PCR)-based methods. [3].
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Since the choice of treatment is determined by the grade of the tumour, it is essential to 
have a careful review of the biopsy tissue by a pathologist who is experienced in 
diagnosing sarcomas. Complete staging and treatment planning by a multidisciplinary 
team of cancer specialists is required to determine the optimal treatment for patients 
with this disease. In most cases, a combined modality approach of preoperative or 
postoperative radiation therapy is used, rather than the radical surgical procedures that 
were used in the past. The role of chemotherapy is less defined. Because of the evolving 
nature of treatment options for sarcomas, all patients with such lesions should be 
included in a clinical trial whenever possible [3] .
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1.2 Liposarcomas
Liposarcoma, the malignancy of adipocytes (figure 3), was first described by 
Virchow in the 1860s. It is the most common soft tissue sarcoma, comprising 
approximately 17% of all sarcomas, and 3% of all liposarcomas occur in the head and 
neck region, usually in the neck and cheek areas [5].
Because of the rarity of STS most studies deal with the whole group of STSs. The 
causes of STS are only poorly understood. The pathogenesis is based on various 
inherited and environmental factors and also, on pre- existing conditions [6, 7]. Among 
environmental factors exposure to ionizing irradiation, alkylating agents, arsenical 
pesticides and medications, vinyl chloride, immunosuppressive drugs, human 
immunodeficiency virus (HIV), herpes virus type 8 and anabolic steroids are described 
as risk factors. Exposure to chemicals such as phenoxyherbicides, dioxin and 
chlorophenol represent possible risk factors [8, 9]. Inherited conditions associated with 
STSs are Li-Fraumeni syndrome, neurofibromatosis type-1, Gardner’s syndrome, 
retinoblastoma, Werner's syndrome and nevoid basal cell carcinoma syndrome (Gorlin’s 
syndrome). Pre-existing medical conditions such as long-standing lymphoedema 
(Stewart-Treves syndrome) can also cause STS. Several cases with trauma preceding 
development of STS have been reported in the literature but there is no proof of a causal 
relationship [9, 10].
7—  fi'l-.-.-:
W K
Figure 3: Volum e Rendering o f  an abdom inal CT scan w ith I.V. contrast. Late venous phase. Large abdom inal 
liposarcom a with solid structures (no m etastases). All the abdom inal organs are dislocated. N otew orthy: The right 
kidney is m alrotated and its ureter is elongated in an arch extending to the left side, (m odified from 
http://w w w .flickr.com /photos/voxell2  3/4670052 2 17/)
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1.2 .1 Diagnosis
1.2.1,1. Clinical presentation
The localization of the tumour for clinical manifestation is very important. The 
presentation of liposarcoma on the extremities and superficial trunk is often a deep- 
seated mass, frequently of large size, painless or with mild or moderate pain and 
functional disturbances. Retroperitoneal liposarcomas tend to be diagnosed later, with 
more serious bowel symptoms such as gradual abdominal enlargement, pain, anorexia, 
vomiting and intestinal or urinary obstruction .
1.2.1.2 Radiology
Computed tomography (CT) or magnetic resonance imaging (MRI) is used to perform 
radiology but MRI is preferred because of its high intrinsic contrast resolution and 
multiplanar imaging possibilities. The different LS subtypes have different magnetic 
resonance (MR) appearance and diagnostic pitfalls. [11]
It is difficult to distinguish the well-differentiated liposarcomas (WDLSs) of the 
extremities from lipomas, but the most important features that can suggest malignancy 
are: 1) male sex, 2 ) high age, 3) large size, 4) presence of thickened septa and nodular 
and/or globular areas of non-adipose tissue within the fatty lesion composing 25% or 
more of the volume [11, 12].
Dedifferentiated liposarcomas (DDLSs) occur within a WDLS. The radiological 
features suggesting dedifferentiation are areas of focal, nodular non-lipomatous region 
greater than 1 cm in size within a WDLS [12].
Myxoid liposarcomas (ML) often have a characteristic appearance with a large, well- 
defined and multi-lobulated lesion, localized intra and/ or intermuscularly. The high 
water content of the lesion gives atypical appearance on MRI. Adipose tissue in the
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lesion, that constitutes less than 10% of the lesion and is often seen in septa or as small 
nodules in the lesion, is an important diagnostic feature [12].
Pleomorphic liposarcomas (PLSs) and round cell liposarcomas (RCLSs) have a non­
specific soft tissue tumour appearance on MRI, with prominent heterogeneity and, 
often, areas of necrosis and hemorrhage. Small amounts of fat in the lesion suggest the 
diagnosis.
1.2.1.3 Biopsy options
A pretreatment biopsy to diagnose and grade a sarcoma is highly preferred. Biopsy 
should be performed by an experienced surgeon (or radiologist) and may be 
accomplished by open incisional or needle technique. Different biopsy techniques are 
used in the pre-operative diagnosis, depending on the site, size and depth of the lesion 
[13]. Most of the sarcoma centers uses core-needle biopsy or longitudinally oriented 
incisional biopsy for extremity masses. Using Fine needle aspiration (FNA) allows to 
reduce the small risk of seeding sarcoma cells to the surrounding. Fine needle aspiration 
is also useful for diagnosing intra-abdominal, retroperitoneal and mediastinal masses. 
The disadvantage of using FNA is that the cellular samples are small and it can be 
difficult to ascertain the tumour grade and histological type. For surgical planning, it is, 
however, most important to decide whether the lesion represents a soft tissue tumour 
and whether the tumour is benign or malignant [14]. A 90% diagnostic accuracy of 
differentiating a benign lesion from a liposarcoma has been reported with FNA 
cytology. An experienced cytopathologist is essential for this method to be successful, 
as is well-functioning collaboration between the radiologist, orthopedic surgeon and 
cytopathologist [15, 16].
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1.2.1.4 Method to detect and identify difference types o f FUS-CHOP
Initially Fluorescent in situ Hybrizidation (FISH) is used to detect the chimera, then 
reverse transcription-polymerase chain reaction (RT-PCR) is used to identify the 
difference types of FUS-CHOP fusion gene transcripts, pathognomonic for ML. This 
method helps to differentiate between ML and other myxoid variants of STSs, such as 
myxoid malignant fibrous histiocytoma (MFH), myxofibrosarcoma, predominantly 
myxoid WDLS of the retroperitoneum, and intramuscular myxoma [17].
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1.2 .2 Treatment
1.2 .2.1. Surgery
The surgical procedure is considered the most important treatment modality. Ideally, the 
biopsy site should be excised en bloc with the definitive surgical specimen. Radical 
excision/entire anatomic compartment resection is not routinely necessary. Surgical 
clips should be placed to mark the periphery of the surgical field and other relevant 
structures to help guide potential future radiation therapy. If closed suction drainage is 
used, the drains should exit the skin close to the edge of the surgical incision (in case re­
resection or radiation is indicated).
Wide local excision with clear margins is important for local tumour control [18]. Until 
2006 the margins were reported as:
• “Intralesional m a r g in the dissection passed within the lesion and microscopic 
or macroscopic tumour was left at the margin of the resection.
• “Marginal m a r g in the lesion was removed in one piece but the dissection was 
through the pseudocapsule or reactive tissue surrounding the lesion.
• “Wide margin”: the tumour was removed en bloc completely surrounded by a 
cuff of normal tissue but the dissection was within the involved compartment.
• “Myectomy” : the muscle in which the tumour was located was removed 
without opening its fascia.
• “Compartmental resection” was performed when the tumour involved 
compartment, beyond the fascial septa of the involved compartment, was 
removed en bloc.
Since 2006 there has been a modification in the classifications of margins as follows:
• “Positive margin”: a gross tumour or microscopic tumour is left at the margin, 
which is reported.
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• “Negative margin no microscopic tumour at the margin. The extent of the 
margin is reported.
More than 20 mm of normal tissue around the tumour, or fascia completely surrounding 
the tumour is classified as “wide margin” [3, 18].
1.2.2.2 Radiotherapy (RT)
The goal of RT is to kill tumour cells selectively, without irreversibly injuring adjacent 
normal tissue. This is done by exploiting two abnormal aspects of tumour behavior: 
decreased ability for repair and increased susceptibility to ionizing radiation damage. 
Tumours are generally less able than normal tissue to repair DNA damage, owing to 
defective repair mechanisms. Tumour cells are also comparatively more radiosensitive 
than normal tissues, as they are more frequently in radiosensitive cell-cycle phases. 
Thus, dividing the radiation dose into a number of treatment fractions provides two 
advantages that further exploit the biologic differences between tumour and normal 
tissue: it allows DNA repair to take place within the normal tissues, and it allows 
proliferating tumour cells to redistribute through the cell cycle and move into the more 
radiosensitive phases [19].
Radiotherapy in STS is considered to be an established method for elimination of
microscopic tumour [20]. Radiotherapy as an adjunct to limited surgical excision was
shown to achieve lower local control than radical resection alone and no differences in
overall survival [21-24]. In a prospective randomized trial, it was shown that adjuvant
postoperative radiation therapy in combination with conservative surgery improves
local control for extremity STSs of both low and high grade in patients with
microscopic negative, marginal or minimal microscopic positive surgical margins. No
difference was found in overall survival. It is interesting to note that in the low-grade
group 40% of lesions were of the radio-sensitive ML type [24].
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Most STS that are unresectable do not respond to radiation therapy with sufficient 
tumour volume regression. Few studies on this subject report a 5-year local control rate 
of approximately 30-45% for unresected STSs treated with radiotherapy alone, median 
61- 64 Gy [25, 26]. Local tumour control was related to tumour size at radiation, and 
radiation dose. In previous studies, it was reported that patients who received doses of 
less <63 Gy had a 5-year local control rate of 2 2 % compared with 60% for patients 
who received doses of 63 Gy or more [24]. Local control at 5 years was 51%, 45% and 
9%, respectively, for tumours <5 cm, 5-10 cm and >10 cm. However, there are some 
reports on high radiation responsiveness in ML, both as case reports in unresected 
tumours and in a pre-operative setting[27-31].
1.2.2.3 Chemotherapy
Chemotherapy has been used in both a palliative setting and as adjuvant therapy for 
high-grade STSs. If the cancer is disseminated, the aim of chemotherapy is to shrink 
tumours and reduce the pain and discomfort they cause, but cure is unlikely. While a 
symptomatic benefit is frequently seen with chemotherapy for advance STS, a survival 
benefit has not been defined. In the adjuvant setting, several studies have demonstrated 
that doxorubicin or ifosfamide-based chemotherapy treatment gives benefits in terms of 
reduced local recurrence rate and distant metastases but no overall survival benefit [32- 
36]
1.2 .3 Histological subtypes
The different histological subtypes of liposarcoma all have different appearance and 
clinical behavior . The histopathological low-grade group constitutes of WDLS (grade 
I) and ML with <5% round cells (grade II) and the high-grade group of ML with >5% 
round cells (grade III or IV) and DDLS and PLS (grade IV)[37].
1.2.3.1 Well-differentiated liposarcomas.
Well-differentiated liposarcomas represent 40-45% of all liposarcomas, with a peak 
incidence between 50 and 60 years [38]. The most common sites are limbs and the 
retroperitoneum. Four different histological subtypes are recognized, which is of limited 
practical importance. Sclerosing and inflammatory types are most often seen in the 
retroperitoneum. Well-differentiated liposarcomas may recur locally but do not 
metastasize unless they undergo dedifferentiation which is the most common in the 
retroperitoneum [39, 40].
According to the update based on the new WHO classification of STSs (2 002 ), the 
preferred term for lesions arising at surgically amenable locations should be “atypical 
lipomatous tumour” but for the lesions arising in the retroperitoneum and mediastinum, 
the term “WDLS” should be used because of their association with significant 
mortality[3 9]. Typical WDLS most often presents as large, deep-seated lesions of the 
thigh followed by lesions in the retroperitoneum. Tumours in the extremities and 
superficial trunk have disease-related mortality near 0% but in the retroperitoneum they 
have a high propensity of local recurrences and the disease-related mortality is high, 
either as a result of uncontrolled local disease or because of dedifferentiation and 
metastasis [41]. The risk of dedifferentiation of the lesions in extremities is <2 % but in 
the retroperitoneum it is >2 0% (3). The typical adipocytic (lipoma-like) WDLS has a 
characteristic morphology with relatively mature fat cells varying in size, enlarged 
atypical nuclei in varying number, low cellularity, few mitotic figures and minimal 
fibrous or myxoid zones. Mono- or multi-vacuolated lipoblasts may be found (figure 4). 
Karyotypic analysis of WDLS/atypical lipomatous tumour has shown the presence of 
extra ring and/or giant marker chromosomes derived from 12 q (13-15) [41]. 
Amplification of MDM2 and CDK4 from this region is frequently seen in WDLS but 
TP53 is very rarely mutated in WDLS (figure 5) [1].
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Figure 4 : (A) A spirate o f  well-differentiated liposarcom a show ing a lipoblast in a background o f  m ature fat (M G G , 
x400); and (B) Histology o f  the same tum our also illustrating a typical lipoblast (H and E, x400)( m odified from 
Diagnostic Cytopathology , 19 SEP 2 011 DOI: 10.1002 /dc.2 1794)
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Figure 5: Cyclin dependent kinase CDK4 binds with cyclin D  to form active com plexes. This results in 
phosphorylation o f  Rb and dissociates pRb from the pRb-E2 F complex. E2 F binds D N A  to upregulate transcription 
o f  genes required to progress to S p h ase) [42]
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1.2.3.2 Dedifferentiated liposarcomas
Dedifferentiated liposarcoma is a high-grade tumour that occurs most commonly in the 
retroperitoneum. The dedifferentiation is most probably time-dependent and the 
majority of the tumours present as de novo lesions [43]. Local recurrence rate after 
surgery of 41-52 %, distant metastasis rate 15-17%, and a disease-related mortality rate 
of 2 8-30% have been reported. The tumours located in the retroperitoneum have 
significantly worse survival than tumours located at other sites [44]. The most common 
histological features in DDLSs are transition areas from WDLS to non-lipogenic 
sarcoma, which in most cases resemble high-grade fibrosarcoma or MFH (figure 6).
A minority of lesions contains only areas of low-grade dedifferentiation resembling 
fibromatosis or well differentiated fibrosarcoma. Independently of the grade of 
dedifferentiation, the behavior of DDLSs is that of a high-grade malignancy. At a 
chromosomal level, DDLS frequently displays the same chromosomal abnormality 
associated with WDLS, i.e. presence of a supernumerary ring or giant chromosome 
derived from the 12 q (13-15) region [43]. TP53 mutations, determined by molecular 
methods, are rare but amplification levels of MDM2 and CDK4 are more frequently 
higher in DDLS than in WDLS (figure 7) [1].
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Figure 6: Exam ple o f  dedifferentiation in a W DL. A t the bottom  o f  the picture the large fat vacuoles o f  the low er 
grade lesion are present. There is an abrupt transition to the m ore cellular dedifferentiated com ponent near the top (H 
and E, x i00).[43 ]
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Figure 7: MDM2 binds to the transcriptional activation domain o f p53, blocking transcription. MDM2 functions as a ubiquitin 
ligase, facilitating proteasomal degradation o f p53. MDM2 releases p53 in response to cellular stress and p53 translocates to the 
nucleus where it acts as a transcription factor to enable growth arrest and apoptosis [42 ].
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1.2.3.3 Pleomorphic liposarcomas
Pleomorphic liposarcoma is the rarest type involving about 10% of liposarcomas [45]. It 
is a high-grade tumour that may mimic MFH or even carcinoma or melanoma. The 
diagnosis depends on the identification of, at least focally, lipogenic differentiation 
and/or lipoblasts that are pleomorphic and multivacuolated with hyperchromatic and 
scalloped nuclei [45, 46] (figure 8). The tumour suppressor gene TP53 in PLS is often 
mutated together with complex chromosomal imbalances, mostly gains but also, though 
less frequently, losses. This subtype has a high propensity to recur locally and 
metastasize, and a 5 year local recurrence-free and metastasis-free survival of 50-58% 
and 48-58%, respectively, has been reported [45, 47].
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F igure 8: Aspirate from a pleomorphic variant o f liposarcoma. The tumour cells are more numerous and have more ominous 
cytologic features than in other variants o f LS. Occasional cytoplasmic vacuoles are the key to their lipogenous lineage (MGG, 
x400) [45]
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1.3 Myxoid Liposarcoma (ML)
ML is the second most common subtype of liposarcoma and accounts for more than one 
third of liposarcomas and 10% of all adult soft tissue sarcomas. Microscopically ML is 
made up of uniform round-oval primitive non-lipogenic cells and variable numbers of 
uni-multivacuolated lipoblasts intermixed with a well-developed plexiform capillary 
network and embedded in a myxoid matrix composed of hyaluronic acid. Depending on 
the proportion of the cellular component to the stroma and the prevalence of immature 
and mature cellular features ML is divided into a usual or pure subtype, and a round cell 
or cellular (RC) subtype. Usual ML is the most differentiated form and shows low 
cellularity, evidence of lipoblast differentiation and a conspicuous vascular network 
(figure 9) while the RC subtype presents the opposite extreme of the differentiation 
gamut, and shows high cellularity made up of primitive non-lipogenic cells, little or no 
intervening myxoid stroma and a capillary vascular pattern that is not easy to visualize 
(figure 10). Diagnosis of the RC subtype requires >5% hypercellular area [48, 49]. The 
presence of areas with greater cellularity, round cell (RC) is associated with a worse 
prognosis. Thirty-one percent of ML patients develop metastasis with bone metastases 
constituting 56% of these [50]. ML presents inferior survival compared to other low- 
grade sarcoma subtypes with a 5-year disease survival rate of 85% [51]. ML without RC 
is particularly radiosensitive with good local control rates with patients treated with 
adjuvant or neoadjuvant radiotherapy approaching 98% 5-year local control [52].
24
'  .  V  < '
Figure 9: (A) Low power view o f myxoid liposarcoma showing large pools o f  extracellular myxoid material. This pattern is often 
referred to as a “pulmonary edema” like pattern (H and E, *40); (B) High power view o f ML illustrating a characteristic vascular 
arcade (H and E, x2 00) [50]
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Figure 10: (A) Aspiration o f the round cell component o f ML/RLS. The cells have a primitive, small round blue cell appearance 
(H and E, x400); (B) High power photomicrograph o f a “pure” round cell focus o f liposarcoma showing a dense cellular 
proliferation o f cells with high N/C ratio (H and E, ><2 00) [53],
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1.3.1. Molecular Genetics o f Myxoid Liposarcoma
ML is characterized by the recurrent translocation t(12 ;16)(ql3;pll) that results in the 
FUS-CHOP gene fusion that is present in over 95% of cases [53, 54]. In most cases, the 
amino terminal domain of FUS (also known as TLS) is fused to C/EBP homologous 
protein (CHOP, also known as DDIT3 or GADDI53) (figure 11) [54]. In rare cases, an 
alternative translocation event is found t(12 ;2 2 )(ql3;ql2 ) that results in formation of 
the novel fusion oncogene where EWS takes the place of FUS. There is strong evidence 
for these translocations to be the primary oncogenic event in ML as these tumours have 
a relatively normal karyotype, the exception being a few recurrent cases of trisomy 8 
[55, 56]. There are currently 11 different FUS-CHOP chimeras and 4 different known 
EWS-CHOP fusion genes (figure 12 ) [57]. In the most common variants, a portion of 
the amino terminus of FUS is fused to the entire coding region of CHOP. The FUS- 
CHOP transcript type does not appear to have a significant impact upon clinical 
outcome and RC content, necrosis and p53 expression remain stronger predictors of 
clinical outcome [53, 58].
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Figure 11: CHOP break apart FISH probe applied to a tumour with a RC component. The tumour cell has one fusion signal 
(arrowhead) and two break apart signals (arrows), indicating a rearrangement o f one copy of the CHOP gene region (12 q!3) [49].
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Figure 12: Classification o f FUS-CHOP fusions [54]
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There is evidence that the fusion transcript type may influence response to therapy 
although the studies are hindered by sample size [59]. Understanding how the FUS- 
CHOP fusion causes ML and uncovering any further molecular abnormalities in the 
disease will aid in development of novel targeted therapies [42, 60].
FUS belongs to the FET family of RNA-binding proteins that consists of FUS, EWS, 
and TAF15 as well as the closely homologous, Drosophila SARFH [61]. These 
structurally and functionally related RNA-binding proteins are composed of an SYGQ- 
rich amino terminus, an RNA recognition motif, a zinc finger motif, and at least one 
RGG rich repeat region [62]. FET proteins are expressed in most human tissues and 
appear to be regulated following differentiation in neuroblastoma cells and 
spontaneously differentiating human embryonic stem cells [62, 63].
Both FUS and EWS have been shown to localize to the nucleus and the cytoplasm, bind 
RNA, and are also involved in nucleo-cytoplasmic shuttling [63]. The FET family 
associate with various complexes involved in the induction of transcription, including 
RNA polymerase II (RNAPII), which regulates transcription and TFIID complexes, that 
binds DNA as part of the transcriptional machinery [64], implicating both FUS and 
EWS in transcriptional control. In addition, FUS has recently been shown to repress 
transcription of RNA polymerase III (RNAPIII), suggesting a broader role in regulation 
through multiple different mechanisms [65, 66]. Noncoding RNAs are capable of 
allosterically modifying FUS in response to DNA damage to inhibit the transcription 
factor CREB-binding protein (CBP) and p300 histone acetyltransferase activity, 
resulting in transcriptional inhibition at the cyclin D1 promoter in cell lines and shows a 
further role for FUS in transcriptional control. FUS has also been implicated in the 
DNA damage response as a downstream target of ATM, which can detect and 
coordinate DNA repair [42].
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The CHOP gene, (also known as “C/EBP-homologous protein (CHOP)” and “growth 
arrest and DNA damage inducible (GADD 153/') encodes for a nuclear protein, which 
is a member of C/EBP family. CHOP is induced in response to endoplasmic reticular 
stress and is involved in mediating cell death in response to such stress stimuli, e.g. 
treatment with alkylating agents, ultraviolet (UV) light, nutritional deprivation, 
oxidative stress and stress that disturb endoplasmic reticulum function. [66]. CHOP 
also plays a role in regulating differentiation in adipocytes by interfering with the 
process in response to metabolic stress [67]. One of the important roles of CHOP is to 
heterodimerize with other members of the family, serving as a dominant negative 
protein by altering their transcriptional potential [67]. Within the constitutively active 
FUS-CHOP chimeras, CHOP retains the heterodimerization and DNA-binding domains 
and it is thus proficient in shortcutting the normal C/EBP activities [67, 68]. Among the 
activities of this important class of transcription factors, genetic and biochemical 
experiments established the key role of three members C/EBPa, p, and 5 in adipocyte 
differentiation. C/EBP p and C/EBP5 play redundant roles in the early phases of 
commitment, whereas C/EBPa becomes active and important in the later phases leading 
to terminal differentiation [69, 70].
The C/EBPs belong to the basic-leucine zipper class of transcription factors, six 
isoforms have been described, all of which act as homo- and/or heterodimers formed via 
a highly conserved bZIP domain [67]. The bZIP class of leucine zipper is characterized 
by juxtaposition of a region rich in basic amino acids to a region containing a repeat of 
hydrophobic amino acids, often leucines. The two regions form an a-helical 
conformation, one of this two regions dimerizes with an analogous region of a second 
bZIP protein forming a leucine zipper dimer. The basic region of the paired subunits 
interacts with a DNA binding site know as CAAT box . During adipogenesis, regulated 
expression is seen for several C/EBP family members, and recent gain- and loss-of-
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function studies indicate that these proteins have a profound impact on fat cell 
development [69]. In cultured preadipocytic cell lines that have been induced to 
differentiate, C/EBPp and 8 mRNA and protein levels rise early and transiently. 
C/EBPa, on the other hand, is induced later in the differentiation process, slightly 
preceding the induction of most of the end-product genes of fat cells. The proadipogenic 
role of C/EBPp and 8 was originally made clear in gain-of-function experiments in vitro 
[69, 70]. Ectopic expression of C/EBPp is sufficient to induce the differentiation of 
3T3-L1 cells without the addition of hormonal inducers; similar experiments with 
C/EBPS reveal that prodifferentiative agents are still required, but adipogenesis is 
accelerated. C/EBPp may also be able to determine cells to the adipocytic lineage as 
well as promote their differentiation; ectopic expression of C/EBPp (but not 8) in NIH- 
3T3 fibroblasts is permissive for adipogenesis in the presence of hormonal inducers 
[70].
The involvement of C/EBPa in adipogenesis is also strongly supported by in vitro data. 
Overexpression of C/EBPa in 3T3-L1 preadipocytes induces their differentiation into 
mature fat cells [69], and the expression of C/EBPa antisense RNA in these cells blocks 
this process. Animals that carry a homozygous deletion of the C/EBPa gene have 
dramatically reduced fat accumulation in WAT and BAT pads [71]. However, since 
these mice succumb to hypoglycemia within the first week of life as a result of a failure 
to activate gluconeogenesis in the liver, their reduced adiposity needs to be considered 
in light of their severe metabolic derangement. Indeed, the reduction in adiposity 
appears to be primarily a result of depressed lipogenesis, as markers of fat cell 
differentiation are still expressed in the fat pads of these animals. These transcription 
factors are expressed as a cascade in which C/EBPp and C/EBP8, expressed during the 
first stages of the adipocyte differentiation program, induce the expression of C/EBPa 
and PPARy2 , the master regulator of adipogenesis [71-73]. PPARy is a member of the
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nuclear hormone receptor superfamily and heterodimerize with another nuclear 
hormone receptor (the retinoid X receptor, or RXR) to bind DNA and be 
transcriptionally active. PPARy exists as two protein isoforms generated by alternative 
promoter usage and alternative splicing. PPARy2 is 30 amino acids longer at the amino 
terminus than PPARy 1, and is the dominant isoform found in fat cells [73]. PPARy 1 is 
present at lower levels in adipose tissue and in a variety of other cell types, including 
macrophages, type II pneumocytes, and the epithelia of colon, bladder, breast, and 
prostate. However, PPARy2 is more efficient at induce terminal differentiation in in 
vitro and in vivo models. A positive feedback loop mechanism between PPARy2 and 
C/EBPa enhances their activities. This transcriptional cascade finishes with the 
expression of markers of mature adipocytes such as ap2 , adiponectin and adipsin [74- 
76]. It is possible that FUS-CHOP may interfere in cellular differentiation. In support, 
various studies suggest that FUS-CHOP functions by inhibiting adipogenesis and 
maintaining immature adipocytes in a continuous cycle of proliferation without 
differentiation. Introduction of FUS-CHOP into mice, where expression of the 
transgene is driven by the ubiquitously expressed elongation factor la  (EFla) promoter, 
results specifically in liposarcomas with inherent induction of adipocyte specific genes 
such as PPARy [77]. Further evidence of adipogenic differentiation block resulting 
from FUS-CHOP expression was shown in vivo where mice expressing FUS-CHOP 
under the control of the aP2 promoter, which is a downstream target of PPARy 
expressed in immature adipocytes, failed to develop liposarcomas, indicating 
interference between PPARy and aP2 activation (figure 13) [78, 79].
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F ig u re  13 : Adipogenesis pathway: (A) PPARy and C/EBP family transcription factor are involved in adypocite differentiation. 
Transcriptions are expressed in cascade in which C/EBP8 and C/EBPp, expressed during the first stages o f  the adipocyte 
differentiation program, induce the expression o f C/EBPa and PPARy, the master regulator o f adypogenesis. (B) FUS-DDIT3 
blocks the adipocyte differentiation program in mesenchymal cell progenitors by interfering with the PPARy and C/EB Pa activities 
at the transcriptional level [79].
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An emerging clinically relevant targetable pathway in ML involves the receptor tyrosine 
kinases (RTKs) MET, RET, and the PI3K signaling cascade. RET is overexpressed in 
ML compared to normal fat [80] and high expression has been correlated with poor 
metastasis-free survival in ML [81]. RET, IGF1R and IGF2 are highly expressed in ML 
and promote cell survival through both the PI3K/Akt and Ras-Raf-ERK/MAPK 
pathways [81, 82]. A panel of tyrosine kinases including PDGFRB, EGFR, MET, RET, 
and VEGFR2 are activated in both treated (with chemotherapy/radiotherapy or 
trabectedin) and untreated cases of human ML [83]. In addition to activation of MET in 
clinical ML specimens, MET and the ligand HGF are potentially regulated by FUS- 
CFIOP. Both MET and HGF are highly expressed in mesenchymal progenitor cells 
transfected with FUS-CHOP in a disease mimicking allograft mouse model [77]. In a 
small clinical cohort, specific Akt phosphorylation was observed in the RC variant and 
2 treated cases that harbored PTEN mutations, implicating RTK pathways signaling 
through Akt in ML [81].
FLT1 (that encodes the VEGFR1 protein) is expressed as an indirect downstream effect 
of FUS-CHOP expression in both FUS-CHOP transfected HT1080 (fibrosarcoma) and 
ML cell lines. However VEGFR tyrosine kinase inhibitors did not have a notable 
impact on proliferation in MLPS cell lines indicating a separate role in these cells [77, 
84, 85].
Akt activation, particularly in the RC variant, suggests a role for phosphoinositide 3- 
kinases (PI3K). PI3Ks are activated upon phosphorylation of membrane bound receptor 
tyrosine kinases [82 ]. PI3K can activate many proteins including the protein serine- 
threonine kinase Akt, which when phosphorylated causes downstream activation and 
ultimately cell growth, cell cycle entry, and subsequently survival. The PI3K 
holoenzyme complex is composed of both a catalytic and regulatory subunit. The 
catalytic subunit, PIK3CA, encodes the pi 10a isoform and is commonly mutated in
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various cancer types including breast, colon, brain and gastric malignancies [86, 87]. A 
recent study showed 18% of ML patients (n = 71) had PIK3CA mutations in either the 
helical (E542 K and E545K) or kinase (H1047L and H1047R) domain.
The presence of a PIK3CA mutation was associated with a shortened disease specific 
survival. Barrettina et al. showed one tumour with a homozygous PTEN  mutation [88, 
89] . PTEN is a tumour suppressor that dephosphorylates phosphoinositide substrates to 
negatively regulate the Akt signaling pathway, demonstrating more mechanisms for 
perturbation of the pathway (figure 14)[ 88].
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F ig u re  14: The PI3K pathway is highly active in MLPS, and this is potentiated at least in part by overexpression, and/or activation 
through RTKs such as MET, RET and VEGFRs. Upon ligand binding, RTKs activate downstream activation o f genes involved in 
multiple cell processes such as cell survival, proliferation, and angiogenesis. These signals are mediated through the PI3K/Akt 
pathway and also through RAS. PIK3CA and PTEN mutations and Akt activation have also been documented in M L [42 ].
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1.4 Novel Therapeutic Implication in Liposarcomas.
The current modalities available (chemotherapy, surgery and radiotherapy) for the 
treatment of liposarcoma are limited, creating a need to identify novel therapeutics.
1.4.1 MDM2 antagonist
The activity and level of the tumour suppressor protein p53 is negatively regulated by 
the E3 ligase MDM2 , which controls both its ability to trans-activate downstream 
genes and its proteasome mediated degradation. In tumours with wild type p53, its 
activity may be blocked through amplification and overexpression of the MDM2 
locus.2 ,3. Due to the central role of p53 in oncogenesis and therapy response, the 
p53-MDM2 interaction is an interesting target for small-molecular therapy [90]. The 
goal is to reactivate p53 and induce downstream effects leading to programmed cell 
death or increased response to DNA-damaging therapies, as has been pursued by 
several groups. One of the most promising MDM2 antagonists is Nutlin 3A, which 
has been shown to activate wild type p53 in cancer cell lines, inducing cell cycle arrest 
and apoptosis in various cell lines, including osteosarcomas with amplified MDM2 
[91, 92]. The amplification of MDM2 is much more frequent in the more common 
subtype of well-differentiated liposarcoma (WDLS) and dedifferentiated variants, 
where virtually all tumours contain complex marker chromosomes that always include 
multiple copies of MDM2 .
Translation from in vitro to attractive in vivo therapeutic intervention requires that 
drugs pass Phase I requirements [93]. A small molecule inhibitor was designed, spiro- 
oxindoles as a new class of inhibitors of the MDM2 -p53 complex. Spiro-oxindoles 
bind to MDM2 with high affinity and activates the p53 pathway, inhibiting the growth 
of neoplastic cell lines with wild-type p53 [93, 94] . MI-2 19, the lead compound in 
this class, demonstrates greater potency along with a superior pharmacokinetic profile
38
than Nutlin-3a (a MDM2 antagonist, a p53 activator and an apoptosis induce) [91, 
93]. MI-2 19 has been shown to stimulate rapid p53 activation in tumour xenograft 
tissues with resultant inhibition of cell proliferation [91, 93, 95, 96]. Studies using both 
Nutlin-3a and MI-2 19 show a p53 and p2 1 dependent cell cycle arrest in normal cells, 
along with p53 dependent cell death specifically in tumour cells [94]. Importantly, 
Nutlin-3a and MI-2 19 do not cause visible toxicity to animals, as assessed at necropsy 
[97].
Two others oral MDM2 inhibitors that have been recently entered the clinical setting , 
JNJ-2 6854165 (Ortho Biotech; Johnson & Johnson) and R7112 (Hofffnann-La 
Roche). Both agents are being tested in advanced stage or refractory solid tumours 
Phase I trials [42]. In addition, AT-2 19 (a derivative of MI-2 19) is in preclinical 
studies with Phase I trials planned. Of relevant interest, an MDM2 antagonist 
RO5045337 is about to recruit for a Phase I trial in liposarcoma patients [42].
1.4.2. CDK4 Antagonists
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This 
protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2 . 
It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 
phase progression. The activity of this kinase is restricted to the Gl-S phase, which is 
controlled by the regulatory subunits D-type cyclins and CDK inhibitor p i6 (INK4a). 
This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene 
product (Rb). Mutations in this gene as well as in its related proteins including D-type 
cyclins, p i6 (INK4a) and Rb were all found to be associated with tumourigenesis of a 
variety of cancers. Multiple polyadenylation sites of this gene have been reported.
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Like p53, the Rb pathway is almost universally deregulated in cancer, although (unlike 
p53) it has important developmental as well as tumour suppressor roles. The Rb 
pathway controls the cell cycle at the Gl/S checkpoint.
A range of CDK4 antagonists are in clinical development, most in early-phase study, 
and are fairly nonselective, with effects on several CDKs. Genetic ablation of CDK2 , - 
4, and -6 in mice seems dispensable in most normal cell cycles, but depends on CDK1 
[98, 99].
First generation pan-CDK inhibitors include Flavopiridol and Seleciclib (R- 
Roscovitine), inhibiting CDK1, CDK2 , CDK4, CDK6, CDK7, and CDK 1, CDK2 , 
CDK7 and CDK9 respectively [99].
Flavopiridol causes arrest in G1 and G2 phases in a range of solid tumour cell lines. 
Flavopiridol is more potent if tumour cells are in S phase [98, 100-102]. Matranga and 
Shapiro [102] demonstrated recruitment to S phase using hydroxyurea, gemcitabine and 
cisplatin, followed by flavopiridol resulting in sequence-dependent cytotoxic synergy 
[102-104]. Flavopiridol and Seliciclib have been investigated in Phase I/II trials for 
hematological and solid tumours including sarcomas. Trials include Flavopiridol as a 
single agent and in combination with taxanes where synergism has been noted [104]. 
Both Flavopiridol and Seleciclib have shown disappointing results relating to clinical 
outcome and intolerable side effects [105, 106].
Newer generation CDK inhibitors include PD0332 991, ZK 304709, R 547 and 
P1446A05. All are available in Phase I and II solid tumour trials [105] . PD0332 991 is 
one of two more selective CDK inhibitors specific for CDK4 and CDK6. Preclinical 
data showed inhibition of cell growth through G1 arrest in pRb-positive tumour cell 
lines and antitumourigenic effects in xenograft models of colon carcinoma [107]. 
PD0332 991 is available in Phase I and Phase II trials for solid and hematological 
malignancy. Finally, P1446A05 is the only single CDK4 selective inhibitor available.
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No pre-clinical data is publicly available for this compound; however, it has been 
released as a Phase I drug for refractory solid tumour and hematological malignancies 
[105].
1.4.3. PPARy Ligand Agonists
A critical regulator of terminal differentiation for the adipocytic lineage is a nuclear 
receptor peroxisome proliferator-activated receptor y (PPARy) [72, 108, 109]. PPARy is 
an attractive target in undifferentiated lipomatous tumours such as DDLPS and ML. 
PPARy forms a heterodimeric complex with the retinoid X receptor (RXR). This 
complex regulates transcription of adipocyte-specific genes by binding sites on DNA. 
Agonist ligands for the PPARy receptor have been shown to induce terminal 
differentiation of normal preadipocytes in human liposarcoma cells in vitro [108].
A  Dana-Farber Cancer Institute Phase II clinical trial used Troglitazone, a synthetic 
PPARy ligand, in patients with high-grade liposarcoma. This trial enrolled three 
patients. All patients showed histologic and biochemical differentiation in vivo, with 
reduction in immunohistochemical expression of the proliferation marker Ki-67 [108] . 
A more recent study with 12 patients with Rosiglitazone, belonging to the same class of 
drugs (thiazolidinediones) as Troglitazone, was not as promising, with median 
progression free survival of 5.5 months. Treatment did not produce any convincing 
adipocytic differentiation with no correlation between the high expression of 
differentiation genes that was found in two patients, and clinical response [110].
1.4.4 Receptor Tyrosine Kinase Pathway Inhibitors
The high frequency of PIK3CA mutation suggests a role for PI3K inhibitors in ML. The
non isoform-specific PI3K inhibitors, Wortmannin and LY2 94002, have been widely
41
used in biological research but are not particularly suited to clinical work due to their 
lack of specificity, Wortmannin's instability and LY2 94002's low potency [111]. GDC- 
0941 and PX-866 are promising PI3K inhibitors curently in clinical trials that have low 
nanomolar potency against class I isoforms of PI3K [112-114]. In lung cancer cell lines 
and xenograft models, PIK3CA mutants are more sensitive to GDC-0941[115]. 
Similarly, PIK3CA mutant and PTEN-null tumours were sensitive to PX-866 in 
xenograft models, and phase I clinical trials for solid tumours are currently 
underway[114]. The Rapamycin derivateve Everolimus inhibits the mTOR complex-1 
(mTORCl), which is a downstream effector of PI3K. Both H1047R and E545K PI3K 
mutant cells are sensitive to Everolimus [116]. PIK3CA mutated ML represents an ideal 
candidate for PI3K inhibition.
As MET is activated in ML and there are many MET pathway inhibitors currently in 
development and in clinical trials [117], ML may be a good candidate for MET 
inhibition. For example, the novel and promising inhibitor Foretinib (XL880) inhibits 
multiple kinases including both MET and VEGFR2 and exhibits extensive biological 
activity and clinical efficacy in an early Phase I clinical trial in metastatic or 
unresectable solid tumours [118].
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1.5 T rab ected in
In the continuous search for effective anticancer therapy, nature provides an attractive 
source of new therapeutic candidate compounds [119-121]. At present, over 60% of the 
currently approved drugs for the treatment of cancer are derived from natural sources, 
including plant-derived agents, such as the taxanes, paclitaxel and docetaxel, and 
microbe-derived agents, such as bleomycin and doxorubicin [121]. Currently, there is a 
growing interest for potential cytotoxic agents originating from organisms in the sea 
[120, 122, 123]. Due to advances in diving techniques and deep-sea sample collection, 
the marine ecosystem became an accessible source for new chemical classes. 
Furthermore, new technologies in aquacultures provided a means for the production of 
these potential drugs on a larger scale, which facilitated the development of these agents 
[124-126]. The first living organisms in the sea appeared about 700 million years ago 
and, ever since, evolution has provided these organisms with defense mechanisms to 
survive in the hostile environment [126]. It was suggested that their survival is partly 
due to the excretion of highly toxic products [126].
Ecteinascidia turbinate (figure 15) is a translucent tunicate that grows preferentially on 
mangrove roots in the Caribbean Sea. The potent cytotoxicity of its extracts was first 
discovered in the late 1960s; however, the purification of active compounds was not 
established until 1986 [127]. Trabectedin (Yondelis, ET-743) was one of the isolated 
compounds and it was selected for further development as an anticancer agent based on 
its promising cytotoxic activity as well as its abundance in the tunicate. Recently, the 
features of trabectedin have been briefly reviewed in relation to its potential use in 
treatment of soft tissue sarcomas [128,129].
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F ig u re  15: Ecteinascidia turbina (m odfied from http://sarcom ahelp.org/research_center/ET-743.htm l)
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1.5.1 Mechanism of action
1.5.1.1 DNA binding
Trabectedin (figure 16) is formed by a monobridged pentacyclic skeleton composed of 
two fused tetrahydroisoquinoline rings (A and B), linked to a 10-member lactone bridge 
through a benzylic sulfide linkage, and attached through a spiroring to an additional ring 
system made up of a tetrahydroisoquinoline (subunit C).
In contrast to traditional alkylating agents that bind guanine at the N7 or 06  position in 
the major groove of DNA, trabectedin binds to the exocyclic N2 amino group of 
guanines in the minor groove of DNA through an iminium intermediate generated in 
situ by dehydration of the carbinolamine moiety present in the ring A. The 
carbinolamine moiety is essential for the pharmacological activity of trabectedin, as 
related compounds without this reactive group (e.g., ET-745) were 100 times less active 
than trabectedin. The resulting adduct is additionally stabilized through van der Waals 
interactions and one or more hydrogen bonds between rings A and B, with neighboring 
nucleotides in the same or opposite strand of the DNA double helix, thus creating the 
equivalent to a functional interstrand crosslink (figure 16). In fact, hydrogen-bonding 
rules seem to determine the DNA-binding sequence specificity of trabectedin, with a 
guanine located in the central position of triplets 5'-purine-GC and 5'-pyrimidine-GG 
[130]. The binding of the drug in the minor groove induces the formation of DNA 
adducts and bends DNA toward the major groove in a fashion that seems unique for this 
compound [127]. The ring C apparently does not participate in DNA binding, and it was 
proposed to protrude out of the DNA being able to interact with DNA binding proteins, 
such as transcription factors or DNA repair proteins (figures 16 and 17)
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Figure 16: structure o f trabectedin. Subunits A and B are responsible for binding to DNA. The binding o f  trabectedin to 
DNA changes the normal structure o f  the molecule, causing it to bend. In addition, the carbinolamine group functions to alkylate the 
DNA, which is the substitution o f one chemical group for an active hydrogen atom in the DNA. When such a substitution occurs, 
DNA strands are cross-linked and can not replicate, thus causing the cell to die. Subunit C interacts with other molecules, such as 
transcription factors (modified from http://sarcomahelp.org/research_center/ET-743.html) .
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a y
Figure 17 : Schematic o f  the binding mode o f  trabectedin to two favored triplets. Drug covalent bonds are 
represented by solid lines, whereas hydrogen-bonding interactions are represented in dotted lines [131].
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Figure 18: Chemical structure and modeling o f DNA-trabectedin complexes [131].
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1.5 .1 .2  D N A  rep a ir
The Nucleotide Excision Repair (NER) system is involved in the repair of DNA lesions 
caused by ultraviolet light or the bulky DNA adducts caused by carcinogens and 
anticancer agents such as alkylating drugs and cisplatin. Therefore, these cytotoxic 
drugs are usually more effective in NER-deficient cells as compared to NER-proficient 
cells. However, when trabectedin binds to DNA, NER recognizes the complex and 
appears to cause cell death instead of cell repair [132]. This effect was seen at clinically 
relevant concentrations, i.e. 1-10 nM. Based on the proposed mechanism, trabectedin is 
expected to be active against cisplatin-resistant cells, which have an enhanced NER 
system [133]. In vivo experiments have been performed to evaluate the antitumour 
effect of the combination of trabectedin and cisplatin [134]. This effect was either 
additive or synergistic in several tumour types, including sarcomas, non-small cell lung 
cancer, melanoma and ovarian cancer [134]. To gain further insight into this 
mechanism, a bacterial nuclease system (UvrABC) was used to investigate how the 
NER system recognizes and repairs DNA adducts caused by trabectedin [135]. Adducts 
at favored and non-favored binding sites were compared, and it appeared that preferred 
binding sites are repaired less efficiently than the non-preferred adducts. It was 
proposed that the inefficient repair is related to the repair-dependent cytotoxicity [135].
Homologous recombination (HR) and nonhomologous end joining (NHEJ) are involved
in DNA double strand break (DSB) repair. It was found that HR is particularly
important for trabectedin as deficient cells were approximately 100 times more sensitive
to the drug. In contrast, these differences were not observed in NHEJ-deficient cells.
The lack of HR was associated with the persistence of unrepaired DSBs during the S
phase of the cell cycle and apoptosis [136, 137]. The particular sensitivity of cells
deficient in HR seems to be confirmed in the clinic, as the tumour expression of
BRCA1 or BRCA2 seems inversely related to the response in a series of patients with
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sarcomas treated with trabectedin. Although the majority of the DSBs are replication 
dependent and involve the phosphorylation of H2 AX by ATM, recently it has been 
proposed that some of them are also replication independent, transcription coupled, and 
dependent on Mrell-Rad50-Nbsl [138]. As mentioned above, the DNA monoadducts 
are stabilized by hydrogen bonds between trabectedin and nucleotides located in the 
same or in the opposite strand, resulting in a DNA lesion similar to interstrand 
crosslinks.
Recently, the difference between trabectedin-sensitive and resistant chondrosarcoma 
cells was investigated, to gain further insight in its mechanism of action. It appeared 
that the two cell types differed in their migratory ability. The trabectedin resistant cells 
were found to be less invasive than the sensitive cells possibly due to an inability of the 
trabectedin resistant cells to digest extracellular matrix [139].
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1.5 .1 .3  tra n scr ip tio n a l regu la tion
The antitumour activity of trabectedin may involve the interaction of trabectedin with 
DNA. This may result in an impairment of gene regulation, as described for other 
agents that bind to the minor groove of DNA [140-142].
Three types of factors were studied to elucidate effect of trabectedin on regulation of 
transcription: A) oncogene products, such as MYC, c-MYB, and MAF; B) 
transcriptional activators regulated during the cell cycle, such as E2 F and SRF, and C) 
general transcription factors, such as TATA-binding protein (TBP), and NF-Y. No 
inhibition of DNA binding was found for MAF, MYB, or MYC; while for TBP, E2 F, 
and SRF, inhibition was observed at concentrations higher than 50 pM [140]. In vitro 
the inhibition of NF-Y binding was found to occur at trabectedin concentrations in the 
range of 10-30 pM [140]. Since two subunits of NF-Y have a high analogy with histone 
2 B, the effect of trabectedin on nucleosome reconstitution (i.e., a chromatine-like fiber 
formed in vitro by adding histones to DNA) was investigated, and it was found that a 
complete inhibition occurred at drug concentrations of 3-10 pM. These data suggested 
that the mode of action correlates with the ability trabectedin to interfere with the 
binding of regulatory proteins to DNA, thus altering their specific function. NF-Y, one 
of the factors that was preferentially affected by trabectedin, activates the CCA AT 
element present in 25% of eukaryotic promoters, including many promoters that 
regulate genes controlling the cell cycle. Based on this observation, were performed 
experiments in cell cultures using NIH-3T3 fibroblasts.
NIH-3T3 were transfected with a reporter gene under the control of HSP70 promoter 
which contains two CCA AT boxes activated by NF-Y. In this system, it was shown that 
a brief treatment with trabectedin in the nM range inhibited the transcription of HSP70 
[143]. It was postulated that physiologically relevant concentrations of trabectedin could
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affect the transcription of other NF-Y mediated genes such as MDR1 [144]. It was 
demonstrated that trabectedin can inhibit activation of the MDR1 promoter by multiple 
inducers at clinically achievable concentrations. Moreover, constitutive MDR1 
transcription is not affected appreciably under these conditions, suggesting that, in the 
clinic, trabectedin may selectively inhibit activation of MDR1 expression in tumour 
cells without affecting constitutive expression in normal cells.
Further studies indicated that several genes are either down or up-regulated in HCT116 
and MDA-MB-435 cell lines exposed to trabectedin. It should be noted that not all the 
effected genes were transcriptionally regulated by NF-Y, suggesting that other 
mechanisms might be involved in the transcriptional effects caused by trabectedin 
[145].
The orphan nuclear receptor, SXR, coordinately regulates drug metabolism through the 
induction of transcription of the gene encoding for the cytochrome P450 enzyme, 
CYP3A4, as well as the transcription of MDR1, a gene encoding Pgp, a glycoprotein 
that regulates the efflux of several compounds including anticancer drugs. It was shown 
that many xenobiotics, including drugs such as taxol, activate SXR, thus enhancing both 
drug metabolism and its Pgp-mediated drug clearance. Trabectedin was found to be able 
to inhibit SXR and consequently suppressed MDR1 gene. The inhibition of SXR, which 
appears to have several detoxification genes as targets, might be relevant to the toxicity 
of trabectedin and of other drugs combined with trabectedin [146]
Others studies proposed topoisomerase I as a putative target of trabectedin . However it
should be noted that these experiments were performed by treating tumour cells with 10
pM trabectedin, a concentration 500 to 1,000-fold higher than optimal 50% inhibitory
concentration values. In addition, there is evidence suggesting that topoisomerase I may
not be the primary target of trabectedin, since the drug was equally active in both wild-
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type and DNA topoisomerase I -  deleted yeast [132].
It was also demonstrated that trabectedin treatment induces the rapid degradation of 
transcribing RNA polymerase II (Poll), only in cells with normal TC-NER function, but 
not in XPD-, XPA-, XPG-, and XPF-deficient cells [147]. However, relatively high and 
not clinically achievable drug concentrations were required to demonstrate this [131], 
therefore this finding certainly requires further research. The observation that 
trabectedin can induce either upregulation or downregulation of the same genes in 
different cell lines can suggest that cell-specific cofactors may play a role in the ability 
of the drug to modulate transcription regulation.
1.5.1.4 Cell cycle perturbations and phase specificity
The effects of 1 hour of trabectedin exposure, evaluated by a BrdUrd/DNA biparametric 
flow-cytometric analysis, showed that cells in the S phase during drug treatment 
progressed through this phase of the cell cycle more slowly than control cells [148].
In addition, cells that were in the G1 phase progressed through the S phase slowly. At 2
4 hours, a high percentage of trabectedin-treated cells were arrested in the G2 phase,
and only 12 0 or 168 hours afterwards, depending on the cell line, did they progress to
mitosis and restart a new cell cycle. By synchronizing SW620 colon cancer cells by
elutriation, the sensitivity to trabectedin was comparatively evaluated in cells in G l, S,
and G2 -M phases. The results showed that the highest sensitivity to the drug occurred
when cells were in Gl but the lowest occurred when cells were in G2 -M phase. This
finding is of interest, as the majority of available anticancer drugs that interact with
DNA are preferentially effective in S-phase cells, thus indicating a biological effect of
trabectedin that is distinct from those observed for the other drugs.
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Another study showed that trabectedin induced a significant increase in p53 levels, 
which promoted apoptosis in cell lines expressing wild-type p53 [149]. However, p53 
status does not appear to be relevant to the sensitivity to trabectedin, since cytotoxic 
activity does not correlate with the p53 status of different cell lines [148, 149], and the 
cytotoxicity is not significantly different in p53 (-/-) or (+/+) mouse embryo fibroblasts 
or in A2 780 ovarian cancer cells or cells from the A2 780/CX3 subline transfected with 
a dominant-negative mutant TP53 [148].
1.5.1.4 Effects on Tumour Microenvironment
Different types of cancer take advantage of inflammatory components to improve their
survival in organs. A number of growth factors and cytokines (e.g. interleukin (IL)-l,
tumour necrosis factor, IL-6, vascular endothelial growth factor) supports malignant cell
progression and contribute to the suppression of body’s immune defense [150].
Generally two pathways, not mutually exclusive, can be identified as the major affluent
to the inflammatory milieu: 1) the intrinsic one (neoplastic cells), where genetic events
(e.g. oncogenes, genetic aberrations), inducing neoplastic transformation, activate the
production of inflammatory mediators; and 2) the extrinsic pathway (inflammatory
leukocytes and soluble mediators) where chronic infections (e.g. viruses, bacteria, and
parasites) significantly increase the risk of cancer. Epidemiological studies estimate that
about 8%-17% of global cancer burden is linked to chronic infections. Indeed, different
common tumours (e.g. bladder, ovarian, gastric, hepatocellular, and colorectal cancer)
are associated with unresolved pathogen infections that fuel inflammation [151, 152].
Strategies to modulate the host micro-environment offer new approaches for anti-cancer
therapies. For these reasons new molecules with anti-tumour and anti-inflammatory
features are looked at with new eyes in the light of the crucial link between
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inflammation and cancer.
At sub-cytotoxic concentrations, trabectedin was shown to inhibit in vitro production of 
prion-inflammatory mediators CCL2 and interleukin IL-6 by monocytes, macrophages, 
and tumour-associated macrophages isolated from ovarian cancer biopsies. These and 
other mediators of the inflammatory response are frequently expressed in the tumour 
microenvironment by infiltrating leukocytes, stromal and cancer cells themselves [153].
CCL2 is a major chemokine promoting monocyte recruitment at sites of inflammation 
and tumours, and its expression significantly correlates with macrophage accumulation 
[154, 155]. In most studies, CCL2 -mediated attraction of macrophages is associated 
with the angiogenic switch and poor prognosis [156-159]. The chemokine CXCL8 is a 
potent mediator of angiogenesis enhancing endothelial cell proliferation, chemotaxis, 
survival, and protease activation [160,161]. Moreover, CXCL8 is directly mitogenic for 
some cancer cells and plays a critical role in tumour growth at metastatic sites [162, 
163]. Similar results were recently seen in myxoid liposarcoma (ML) - a tumour 
particularly sensitive to trabectedin. It was demonstrated that in primary ML cultures, 
IL-6 and VEGF were also down modulated by trabectedin. VEGF is a key angiogenic 
factor, which certainly cooperates with the florid vessel network of ML. IL-6 is a 
growth-promoting and anti-apoptotic inflammatory cytokine [164-166] and a major 
effector signal of activated nuclear factor xB in the promotion of neoplasia [166].
A collaborative study reported PTX3 as one of the most expressed genes in ML [167].
This study showed that trabectedin caused down-modulation of PTX3 mRNA and
protein. PTX3 belongs to the family of acute phase proteins (which also includes CRP
and SAP) and plays an important role in innate resistance to pathogens [168]. In
addition, PTX3 has been shown to be essential for the construction of the ECM by
forming complexes with the TNF-regulated protein TSG6 which, in turn, combines with
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hyaluronan [168]. In the tumour microenvironment, the constitution of a dynamic 
stroma is of overriding importance for the enlarging tumour mass.
Treatment with trabectedin also resulted in a reduction of inflammatory mediators also 
occurs in vivo. Briefly, mice bearing xenograft tumours were treated with three doses of 
i.v. trabectedin; tumour samples were excised 48 hours after the third dose and stained 
for CXCL8, CCL2 , PTX3, macrophage infiltration, and vessels. The number of CD68+ 
infiltrating macrophages significantly decreased after trabectedin from 72 .4 ±8 (mean ± 
SD, three tumours) to 30.2 ± 6 (n = 3; P < 0.05). This was associated with significant 
reduction of tumour vessels. A clear inhibition of CXCL8 and CCL2 staining and a 
partial reduction of PTX3 were observed after treatment [153].
To further investigate the effect of trabectedin on tumour microenvironment, surgical 
ML patient samples were resected after several cycles of trabectedin therapy, and 
compared to the original biopsies. The surgical sample excised after therapy had a 
marked decrease in CD31+ vessels and CD68+ macrophages; PTX3 positivity was also 
significantly decreased after therapy. These findings indicate that the reduction of 
inflammatory mediators observed in vitro with trabectedin may have in vivo 
implications [153]. Besides a direct and strong growth-inhibitory effect on cancer cells, 
trabectedin significantly hampered the production of selected pro-inflammatory 
cytokines such as IL-6, CCL2 , CXCL8, VEGF, and PTX3. The inhibition of some 
mediators was confirmed in vivo in animals bearing ML xenografts, paralleled by a 
marked decrease of infiltrating macrophages and tumour vessels. Downregulation of 
key inflammatory molecules in the tumour microenvironment might be of benefit in 
light of the increasingly clear relationship between persistent inflammation and cancer 
progression [131,153].
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F ig u r e  191 Schematic o f  the unique and complex mode o f  action o f  trabectedin. The antitumour effects o f  trabectedin are due to
multiple mechanisms involving DNA binding in the minor groove, interactions with DNA repair mechanisms, modulation o f  
transcription regulation, and induction o f  microenvironment changes [131].
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1.6 T rab ected in  th era p y  fo r  A d u lt so ft-tissu e  sarco m a s (ST S)
Adult soft-tissue sarcomas (STS) have long been viewed as poorly sensitive to most 
chemotherapeutic agents [169] .When trabectedin was approved in the European Union 
as a further-line of chemotherapy for advanced STS, it was the first drug entering the 
armamentarium of the sarcoma medical oncologist after doxorubicin in the 1970s and 
ifosfamide in the 1980s. In the same period, indeed, other drugs were shown to be 
active in selected histological types of STS, giving rise to the so-called ‘histology- 
driven’ medical treatment of this variegated family of rare neoplasms.
Trabectedin contributed to this evolution of thought in STS medical therapy along with 
gemcitabine in leiomyosarcoma and angiosarcoma, taxanes in angiosarcoma, and then 
the new molecularly targeted agents, from imatinib in dermatofibrosarcoma to the new 
agents currently on study. In fact, trabectedin shows selective activity in some STS 
histologies, even with a variegated mechanism of action depending on the histological 
type [170].
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1.6 .1  P h a rm a co k in etic s  a n d  p h a se  I  stu d ies .
After infusion, trabectedin is rapidly cleared from plasma, undergoing an extensive 
hepatic metabolism mainly through the cytochrome P450 3A4 [171]. Trabectedin has a 
high apparent volume of distribution and a half-life of approximately 90 hours [172]. It 
is mainly excreted in the feces but less than 1% is excreted unchanged in the urine or 
feces [173].
In phase I studies (Table 3), different schedules were investigated in patients with solid 
tumours [174]. This schedules range from an intravenous infusion over 1, 3, 2 4, or 72 
hours every three weeks to a weekly infusion for three out of a four-week cycle. The 
dose-limiting toxicities (DLT) were mainly hematological (neutropenia, 
thrombocytopenia) and fatigue. Grade 3-4 hepatic toxicities were also DLT in some but 
not all trials [175, 176]. DLT were transient and not cumulative. Nausea and vomiting 
were managed with 5HT3-antagonists. Fatigue or asthenia grade 3^1 was also 
frequently described (8% to 50%). Tumours responses were observed in soft tissue 
sarcoma, osteosarcoma, melanoma, and breast cancer.
Two schedules were recommended for further phase II studies: 1.5 mg/m2 as a 24-hour 
continuous infusion given every three weeks and 0.58 mg/m2 as a three-hour infusion 
given weekly for three out of four weeks [177].
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Reference Schedule N MTD DLT
Recommen 
ded dose 
for phase
II
Ryan Clin Cancer 
Res. 2001 
Feb;7(2):231-42
72 h infusion 
every 3 
weeks
21 1.2 mg/m2 Transamanitis, 
rhabdomyolysis 
, neutropenia
1.05 mg/m2
Taamma J Clin 
Oncol. 2001 Mar 
l;19(5):1256-65.
24 h infusion 
every 3 
weeks
52 1.8 mg/m2
Neutropenia,
thrombocytope
nia
1.5 mg/m2
Twelves EurJ 
Cancer. 2003 
Sep;39(13):1842-51.
1 h infusion 
every 3 
weeks
40 1.1 mg/m2 Fatigue,. 
neutropenia, 
thrombocytope 
nia
1 mg/m2
3 h infusion 
every 3 
weeks
32 1.8 mg/m2 Fatigue,
hyperbilirubine
mia,
thrombocytope
nia.
1.65 mg/m2
Villalona-Calero Clin 
Cancer Res. 2002 
Jan;8(l):75-85.
Daily for five 
days every 3 
weeks 42
0.325
mg/m2/d
Neutropenia,
thrombocytope
nia
0.325
mg/m2/d
Farouzeh Proc Am 
Soc Clin Oncol 2001
3 h infusion 
weekly for 
three weeks 
of a four 
week cycle
31 0.65 mg/m2 Neutropenia
and
hyperbilirubine
mia
0.58 mg/m2
Table 3: Dose-lim iting toxicity (DLT) and maximum tolerated dose (M TD) in Phase I studies [178]
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1.6 .2  P h a se  II  stu d ies o f  tra b ected in  in  p retrea ted  sa rco m a s
The efficacy of trabectedin was studied in four phase-II studies in pretreated soft tissue 
sarcoma from US and Europe [179,180] of which one was a randomized phase II study 
[181]. Yovine and colleagues [179, 182] investigated trabectedin 1.5 mg/m2 
administered as a 24-hour continuous infusion. Fifty-four patients were enrolled and 
analyzed in two predefined groups. The first group of 26 patients was pretreated with 
only one or two single agents or one combination regimen and the second group of 28 
patients were heavily pretreated with at least three chemotherapeutic agents or two 
combinations. The predominant histology was leiomyosarcoma (n = 22, of uterine 
origin (n = 8), and liposarcoma (n = 6). Two partial responses (3.7% [95% confidence 
interval (Cl): 0.5%-12 .8%]) were reported and both had uterine leiomyosarcoma, four 
(7.4%) patients had a minor response, and nine (17%) patients had stable disease. 
Among the six responding patients, five received prior chemotherapy with ifosfamide 
and doxorubicin. The median progression free survival was 1.9 months after a median 
follow-up of 26 months. At three and six months, 38.8% and 24.1% of patients were 
progression-free, respectively. No difference was noted in progression-free survival 
between the two groups. But the less pre-treated patients had a longer median overall 
survival of 13.7 months versus 7.9 months. Overall, the median survival was 12.8 
months with 30% of patients alive at two years.
Another study reported the results of the phase II trial with trabectedin 1.5 mg/m2 
administered as a 24-hour continuous infusion, conducted in 36 patients pretreated with 
up to two prior chemotherapy regimens [181].
Gastrointestinal stromal tumours (GIST), mesothelioma, osteosarcoma, carcinosarcoma,
Kaposi’s sarcoma, or rhabdomyosarcomawere excluded in this study. The main
histologies were leiomyosarcomas (n = 13), liposarcomas (n = 10), and synovial
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sarcomas (n = 6). One complete response (CR) was obtained in a patient with 
liposarcoma, and two partial responses (PR) in a patient with leiomyosarcoma and in a 
patient with liposarcoma, for an overall response rate of 8% (95% Cl: 2 %-2 3%). Two 
other patients had a minor response. The median time to progression was 1.7 months 
and the median overall survival was 12.1 months with an overall survival rate at one 
year of 53.1%.
The third study published by Le Cesne and colleagues [180] was conducted in eight 
European centers by the European Organization for Research and Treatment of Cancer 
(EORTC) and administered trabectedin at 1.5 mg/m2 as a 24-hour continuous infusion. 
One hundred and four patients were accrued with progressive soft tissue sarcomas 
excluding GIST. Most patients had leiomyosarcomas (n = 43), synovial sarcomas (n = 
18), or liposarcomas (n = 10). There were eight partial responses (in leiomyosarcomas 
[n = 5], synovial sarcoma [n=l], liposarcoma [n=l], and malignant fibrous histiocytoma 
[n = 1]) and forty-five (40.5%) stable disease. Disease stabilization longer than six 
months was measured in 2 6% of patients. Of note the tumour control rate (defined as 
non progressing patients) reached 56% in leiomyosarcomas, 61% in synovial sarcomas, 
and 40% in liposarcomas. After a median estimated follow-up of 34 months, the median 
time to progression was 3.4 months. The progression-free rates at 3, 6, and 12 months 
were respectively 52 %, 2 9%, and 17%. GIST histology has been evaluated separately. 
Among 28 patients none responded, the best effect was disease stabilization in nine 
patients. The median time to progression was less than two months suggesting that 
trabectedin was ineffective in GIST when given alone with this schedule [183]. The 
results of these three phase II studies involving 183 patients were pooled and analyzed 
by Le Cesne.
Leiomyosarcoma remained the main histological subtype representing 41% of patients
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followed by liposarcoma in 14% and synovial sarcoma in 11%. Most patients (95%) 
were pretreated with anthacyclines or ifosfamide and 113 patients were resistant to 
anthracyclines, 81 resistant to ifosfamide, and 63 to both agents. The overall response 
rate was 7.7%. The clinical benefit, defined as the combination of the rate of objective 
response and of minor response and of stable disease, was 51.5%. The median overall 
survival was 10.3 months with an overall survival rate at one year of 47.5% and a 
progression-free survival rate at six months of 19.8%. The clinical benefit was similar in 
patients with bulky disease, with multiple pretreatments, with short previous 
progression-free survival or with early resistance to standard chemotherapy, suggesting 
the lack of cross-resistance and a specific mechanism of action.
A phase II randomized trial was conducted in patients with liposarcoma or 
leiomyosarcoma after failure of anthracyclines and ifosfamide (table 4) [182]. Two 
hundred seventy patients received either trabectedin at 0.58 mg/m2 as a 3 hour weekly 
infusion, three out of four weeks or at 1.5 mg/m2 as a 24 hour continuous infusion every 
three weeks. A significantly longer time to progression was achieved for the three 
weekly regimen reaching 3.7 months and 2.3 months for the weekly regimen (p = 
0.0302, hazard ratio [HR]: 0.734). The median overall survival was 13.8 months for the 
three weekly and 11.8 for the weekly regimen. The clinical benefit favored the three 
weekly regimen even if not statistically significant (58% versus 44%). Neutropenia 
grade 3-4 was described in 47% and 13% on the three weekly and the weekly arm, 
respectively, but it did not translate to a different rate of febrile neutropenia (0.8%). 
Similarly grade 3-4 transaminitis (ALAT) was more frequent in the three weekly arm 
(48% versus 9%), but without clinical consequences.
The results of the compassionate use programs in an unselected population, even though 
most of them included leiomyosarcomas or liposarcomas, were very similar in term of
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efficacy and toxicity [184-187] and in a historical comparison, progression-free survival 
of trabectedin was better than the other active chemotherapeutic agents.
1.6.3. First line trabectedin in sarcomas
In a phase II trial, 36 patients were evaluated with advanced or metastatic soft tissue 
sarcomas [59]. The main histological subtypes were leiomyosarcomas (n = 15) and 
liposarcomas (n = 9). One complete response and five partial responses were observed 
for an overall response rate of 17.1% (95% Cl: 6.6%-33.6%). Responses occurred in 
three patients with liposarcoma, and one patient each with leiomyosarcoma, synovial 
sarcoma, and fibrosarcoma. One patient with a uterine leiomyosarcoma had a minor 
response. The median progression-free survival was 1.6 months and the progression- 
free rate at 6 months was 24.4%. Median overall survival was 15.8 months and overall 
survival at one year was 72 %.
64
M edia
Sub'VPe Media n
Study of Overall Disease n^ . p  q j
type N Sarcoma N response control (months) (months)
Reference
Yovine J Clin Oncol. 2004 Mar Phase II, 28 LMS/Lipo 2 ... 3.7% 24% at six 1.9 12.8
l;22(5):890-9 second line 22 Other 0 months
Garcia-Carbonero J Clin Oncol. 
2004 Apr 15;22(8):1480-90
Phase II, 
second line
23 LMS/Lipo 3 8.3% ND 1.7 12.1
13 Other 0
Le Cesne J Clin Oncol. 2005 Jan Phase II, 53 LMS/Lipo 6 8.1% 53.6% 3.5 9.3
20;23(3):576-84 second line 51 Other 2
Le Cesne Onco Targets Ther. 
2009; 2:105-113.
Phase II, 
second line
183 7.7% 51.4% ND 10.3
Morgan J Clin Oncol 2007 Phase II, 136 3-weekly 5.6 38.9% 3.7 13.8
second line 134 weekly 1.6 24.3% 2.3 11.8
Garcia-Carbonero J Clin Oncol. 
2005 Aug 20;23(24):5484-92.
Phase II, 
first line
24 LMS/Lipo 4 17.1% 20% 1.6 15.8
12 Other 2
Table 4: Efficacy and survival data o f  trabectedin in phase II trials [178].
Abbreviations: ND, no data; LMS, leiomyosarcoma; Lipo, liposarcoma; TTP, time to progression; OS, overall 
survival.1
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1 .6 .4 . E ffica cy  o f  tra b ected in  in  a d v a n ced  p retrea ted  m y x o id  lip o sa rco m a s.
In 2007, Casali group reported their results on patients with myxoid liposarcoma who 
had been treated on a compassionate basis at five institutions in Europe and the USA 
[188]. 51 patients (16 women and 35 men) were included in this retrospective analysis.
All patients started treatment with trabectedin between April 4, 2001, and September
18, 2006. ECOG performance status was 0 in 31 patients, 1 in 18 patients, and 2 in two
patients. 33 patients were diagnosed with a pure myxoid liposarcoma, the other 18
patients had a round-cell component representing 5-90% of the total tumour. FISH
analyses were done in 33 patients, all of whose tumours were found to have the t(12
;16) chromosomal translocation. In 12 of these 33 patients, the availability of frozen
tissue allowed to do RT-PCR experiments. The tissues were sequenced and
characterized as: type II fusion transcript in eight patients; type IV and I in one patient;
type II and IV in one patient; type III in one patient; and type II and III in one patient.
The most common primary tumour site was the thigh. 11 patients presented with
metastatic disease at diagnosis. 27 patients had received adjuvant radiotherapy, and ten
had received adjuvant chemotherapy (anthracyclines) after complete surgery only. The
median number of previous chemotherapy regimens was two (IQR 1-3). Median time
from initial diagnosis to start of trabectedin treatment was 46*3 months (31*4-12 0*1),
and from relapse to start of trabectedin was 24*3 months (12 *3^-2 *3). Four patients had
locally advanced disease when they started trabectedin treatment, and 47 patients had
metastatic disease, with a median of three sites involved (IQR 1-3). All but three
patients had been treated with chemotherapy for advanced disease (i.e., metastatic or
inoperable disease). 46 received both anthracyclines and ifosfamide (of these, 31
patients received anthracyclines and ifosfamide in combination, and 15 patients
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received anthracyclines and ifosfamide in sequence) as first-line chemotherapeutic 
treatment, which is usual practice in some institutions according to individual patient 
data; two patients received antrhacyclines.
558 cycles of trabectedin were administered, with a median of ten cycles per patient 
(IQR 6-14; range 1-2 3). At the time of this analysis, 14 patients were still on treatment 
with trabectedin. 47 patients were treated with the 24-h continuous intravenous schedule 
at the following starting doses: 1-5 mg/m2in 16 patients, 1*3 mg/m2 in 28 patients, and 
1-2 mg/m2 in three patients. Four patients were treated with the 3-h schedule at the 
following starting doses: 1*5 mg/m2 in two patients, 1*3 mg/m2 in one patient, and 1*1 
mg/m2 in one patient. Both schedules were repeated every 21 days. No treatment 
interruption due to toxicity and no unexpected toxic effects or severe adverse events of 
grade 4 were noted.
In a subgroup of 41 patients, a centralized radiological review was done of available 
radiographical images from baseline to progression, to best response, and to treatment 
end; images from study centers in Milan, London, and Boston were used. Only six of 
the 23 patients in this subgroup with a confirmed CR or PR had achieved these 
responses by the first response assessment; out of the other 17 patients, eight patients 
had MR at first assessment, and nine had SD; median time to reach a dimensional 
decrease of the tumour that configured an objective response was 3-6 months (IQR 2-4- 
4-6). In these 17 patients who did not have a confirmed CR or PR by the first response 
assessment, early alterations in tumour appearance detected by CT scan or MRI were 
noted. The hallmark feature was a decrease in tumour density without substantial 
changes in tumour dimensions. The same early signs of decrease in tumour density were 
seen in 11 of the 14 patients with SD as their best response confirmed during central 
review. Median PFS for the three patients with SD but no radiologically detectable
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tissue changes were 2-2 months, 3-4 months, and 5-3 months.
One patient, who had a pericardial metastasis, received nine courses of trabectedin at a 
very low dose intensity (0.167 mg/m2) because of bone-marrow toxicity, and achieved a 
CR that was still maintained after 27 months from treatment initiation. Three patients 
achieved PR as their best response and continued to respond for up to 19, 20, and 23 
cycles, respectively, at which point the patients and the treating clinicians shared the 
decision to stop treatment in view of the long treatment time. These three patients were 
then rechallenged with trabectedin on subsequent disease progression, and two of these 
had a second prolonged disease stabilization, lasting 18 months and 22 months, 
respectively. One patient, who had a multifocal loco regional relapse of a pure-type 
myxoid liposarcoma of the thigh, received four preoperative courses of trabectedin. The 
MRI after four courses of trabectedin showed a marked decrease of contrast 
enhancement without any tumour shrinkage (figure 20).
When this patient’s post-surgery resection specimen was reviewed, both the typical 
plexiform vascular pattern and the immature spindle cell neoplastic component had 
disappeared and were replaced by sclerohyaline material in more than 70% of the 
sample; the remaining areas showed maturation represented by clear adipocytic 
differentiation (figure 21).
68
Figure 20: MRI o f  left thigh showing progressive decrease o f  contrast enhancement without tumour shrinkage [59].
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F ig u re  21: Histological features o f tumour tissue from left thigh before and after trabectedin treatment: Pretreatment (A) 
and post-treatment (B) stained with haematoxylin and eosin; pretreatment (C) and post-treatment (D) with immunostaining with 
CD31 highlighting the vascular network [59],
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A resection specimen from another patient who had a huge abdominal relapse of a 
myxoid liposarcoma with a cellular component up to 50% at diagnosis, and who was 
operated on after 17 courses of trabectedin, showed coagulative necrosis in almost half 
of the sample, sclerohyaline degeneration (20% of the areas), and areas of 
mono vacuolated lipoblasts (figure 22). This patient had achieved an objective PR, 
which was identified by the early appearance of tumour hypodensity on CT scans 
(figure 23).
Although the numbers of patients in this study were too small to draw any definite 
conclusion, no relation between response, trabectedin concentration, infusion 
modalities, other patient characteristics (ie, patient sex, age, location, and grade of 
tumour), and previous interventions (ie, surgery, previous chemotherapy or 
radiotherapy) were apparent. In terms of molecular variants of the CHOP-FUS fusion 
transcript, of the eight patients who carried the type II transcript, one achieved a CR, 
three had PR, and four had SD or MR with tissue changes (one of these patients was 
treated with four cycles of trabectedin and had a major pathological response after 
surgical excision). One patient carrying both the type II and type IV, and another 
carrying both type I and type IV transcripts achieved PR. By contrast, the two patients 
carrying the type III fusion transcript (alone or in combination with another subtype) 
had disease progression.
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Figure 22 : H istological features o f abdom inal-tum our tissue before and after trabectedin tr ea tm e n t : Tum our 
tissue stained with haem atoxylin and eosin before treatm ent (A) and after treatm ent (B -D ): B, deposition o f  
sclerohyaline m aterial and cellular depletion; C, m ature lipoblast-featuring cells; D, necrosis [59].
Figure 23: Sequential CT scans o f abdominal tumour displaying a decrease in tumour density followed by a decrease in tumour 
dimensions in patient 2 1 Basal CT scan (A); after one course o f trabectedin (B); after five courses o f  trabectedin (C); after eight 
courses o f trabectedin (D); and after 11 courses o f trabectedin (E) [59],
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Age,
years
Sex
Location of 
myxoid 
liposarcom  
a
Myxoid 
liposarco 
m a g rad e
DDIT3-
FUS
transcrip t
M etasta tic
sites
Best
response
PFS,
m o n th s
Trabectedin
trea tm e n t
ongoing*
S ta tu s
42 Male Thigh High II Lung CR 8-3 Yes NED
45 Male Thigh High II
Abdominal
cavity PR 16-3 No NED+
65 Male Leg High II
Mediastinum,
pericardium PR 20-5 No AWD
34 Female Thigh High II
Bone, liver, 
pleura, so ft 
tissue PR 11-1 Yes AWD
47 Male Thigh Low II
Pelvis, so ft 
tissue SD 15-2 No NEDt
60 Male Thigh High II Soft tissue SD 12-1 Yes AWD
48 Male Leg Low II
Heart,
pericardium MR 14-5 No AWD
50 Female Thigh High II
Abdominal
cavity MR 6-7 Yes AWD
55
52
Female Thigh Low Hand IV
Abdominal
cavity PR 7-3 Yes AWD
Male Leg High 1 and IV
Bone, 
pericardium, 
so ft tissue PR 18-0 No AWD
58 Male Groin High III
Pelvis, so ft 
tissue PD 1-3 No AWD
53 Male Thigh High II and III
Abdominal 
cavity, so ft 
tissue PD 1-3 No DOD
Table 5: Characteristic o f  12 patients ML who had molecular analysis [59]
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The median PFS on trabectedin of the entire patient group was 14-0 months (95% Cl 
13-1-2 1-0). PFS of the entire patient group at 3 months was 92 % (85-99), and at 6 
months was 88% (79-95). Figure 24 shows the PFS curve of the entire patient group. 
According to RECIST, the median PFS of patients who attained a PR or CR was 20-3 
months (14-0-30-6), and of patients who had SD or MR was 12 -5 months (8-1-2 1-4), 
whereas PFS during previous chemotherapy (ie, before starting trabectedin treatment) 
for 34 patients for whom data were available was 8-4 months (3-1-11-1). This study 
was a retrospective analysis of patients who were given treatment compassionately. 
Other limitations of retrospective studies in general include: the use of nonstringent 
eligibility criteria and absence of a strict follow up protocol, but in this study, the use of 
a protocol for compassionate use attenuated these limitations. Nonetheless, although 
this was not a prospective study, this series was collected on a multicentre basis by 
some of the world’s major institutions with extensive experience with trabectedin.
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F igure 24: Progression-free survival [59].
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In this multicentre, retrospectively studied series of 51 pretreated patients with advanced 
myxoid liposarcoma, trabectedin showed an objective response as measured by RECIST 
of 51% (95% Cl 36-65), with an additional 20 patients achieving MR or SD. The PFS 
was 88% at 6 months. Only five patients exhibited progressive disease. In the subgroup 
of 38 patients who did not have evidence of progression and with available 
radiographical images, 29 showed signs of a tissue response, with substantial 
radiological changes in the density of tumours, often before tumour shrinkage became 
evident.
Indeed, of the 29 patients with radiographical density changes at first tumour 
assessment, an objective response was documented in 17 patients after additional 
trabectedin treatment, and in the others an MR or a prolonged stabilization of disease 
was noted. Moreover, in two patients of this series whose disease was resected after 
preoperative trabectedin, the seradiological findings were consistent with a major 
pathological response, marked by cellular depletion, disappearance of the plexiform 
vascular structure, deposition of sclerohy aline material and increase of mono vacuolated 
lipoblasts.
All these observations suggest that trabectedin induced hypodensity in tumours might 
be a biologically and clinically relevant tumour response to the drug. Indeed, such 
patterns of tumour response have been reported with molecularly targeted treatments, in 
patients with gastrointestinal stromal tumours who receive KIT-kinase inhibition with 
imatinib or sunitinib, and in those with other solid tumours (eg, chordoma) who are 
undergoing molecular targeted treatments [188-191]. Trabectedin might target a 
molecular mechanism with crucial transforming activity in myxoid liposarcoma, 
therefore, accounting for the unexpectedly high response rates in this subtype. CHOP 
fusion oncogenes are found in virtually all myxoid liposarcomas, and preclinical studies
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have shown that trabectedin has transcriptional regulatory functions [60]. In this study, 
in 12 patients with the type of fusion transcript characterized, the two who had early 
progression had the much less common type III transcript, thus further suggesting a 
molecular specificity of action, preliminary and scant though these observations might 
be. These fusion transcript types contain a variable number of exons of fusion (involved 
in t(12 ;16) in malignant liposarcoma [FUS]) and CHOP. Type III is the longest fusion 
transcript, containing the first eight exons of FUS fused to exons 2 to 4 of CHOP. 
Compared with type III, in type II and I, FUS contributes less to the fusion protein 
(exons 1-5 and 1-7 respectively), while type IV is the shortest transcript, comprising 
exons 1-5 of FUS and exons 3-4 of CHOP.
Preclinical studies performed in a myxoid liposarcoma cell line indicate that trabectedin 
modulates transcription, presumably interfering with the fusion oncoprotein FUS-CHOP 
[60]. In the presence of trabectedin, it is transcribed normally, but is not able to activate 
the transcription of target genes. In this sense, the mechanism of action of trabectedin 
could be highly selective in myxoid liposarcoma, with the depression of the expression 
of genes that are crucial for the late phase of adipocytic differentiation. The findings 
observed in myxoid liposarcoma could also be extrapolated to other sarcomas in which 
the translocation results in an altered regulation of the expression of transcription 
factors. For example, some responses observed in patients with Ewing's sarcomas could 
be explained by this mechanism. This disease is characterized by a translocation, most 
frequently resulting in the creation of an aberrant transcription factor (EWS-Flil fusion 
protein), known to regulate more than 70 genes required for the survival of Ewing's 
cells. It was recently shown that trabectedin has a direct inhibitory effect on EWS-Flil 
transcriptional activity [192].
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1.6.4.1 P h a se  II  c lin ica l tr ia l o f  n eo a d iu v a n t trab ected in  in  p atien ts w ith  a d van ced
lo ca lized  m yxo id  lip osarcom a.
Surgery and radio-chemotherapy are the standard therapy for ML, but few data are 
accessible on neoadjuvant treatment . In Grosso study, the results of preoperative 
trabectedin in a cohort of advanced MLs, in two patients with multifocal and huge 
tumour masses, respectively, showed regression of 50%-70% of their tumours, with 
adipocyte differentiation observed in one of them [59], motivated the conduction of the 
present clinical trial.
The aim of this investigative phase II clinical trial was to examine the efficacy and 
safety of neoadjuvant trabectedin in patients with locally advanced ML previously 
untreated with chemotherapy or radiation.
Twenty-nine patients were included and treated with neoadjuvant trabectedin between
16 April 2007 and 12 January 2010. Their demographic and baseline characteristics are
summarized in Table 7. One patient had a non-ML as per centralized review. Metastatic
disease at baseline was disclosed in three patients after their enrollment in the trial. Two
additional patients did not complete neoadjuvant treatment and discontinued therapy
due to adverse events after one and two cycles, respectively. These six patients were
excluded from the primary analysis: pathological response. 3 of 23 ML patients treated
with neoadjuvant trabectedin, achieved a pCR according to centralized pathological
review (13%; 95% Cl, 3% to 34%). In addition, very good and moderate responses were
observed in 2 and 10 patients, respectively. In one of the very good responders, the
presence of residual tumour component was confirmed only trough FISH analysis [59],
which showed the FUS-CHOP translocation in few remaining tumoural cells. In all the
regressed cases, the decrease of cellular components paralleled the replacement with an
acellular stromal component. These observations closely mirror results obtained in
xenografts of ML treated with trabectedin [48]. The decrease in arborizing vascularity
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was also in agreement with the known capability of trabectedin to inhibit 
proinflammatory cytokines release by human ML .
The rate of objective response rate per RECIST was 24% (95% Cl, 10% to 44%), with 
no disease progression. This objective response rate is higher than the 17% previously 
reported in chemotherapy-naive STS patients according to World Health Organization 
criteria (Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) 
for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase 
II and pharmacokinetic study. J Clin Oncol 2005; 23: 5484-5492 )
Apart from the different criteria used to evaluate tumour size, this difference in response 
could be explained by the STS subtypes analyzed. In the present study, all patients had 
ML, which appears to be extremely sensitive to trabectedin, while only 25% of patients 
had this sarcoma subtype in the study reported by Garci aCarbonero et al. [193]. 
Consistently, three of six responses observed in this latter study occurred in patients 
with ML.
A higher response rate by RECIST (50%—51%) has been reported in a retrospective
p
series of ML patients treated with trabectedin [59, 194]. Differences in objective 
response per RECIST could be partially explained by difference in treatment duration 
between the neoadjuvant and the advanced setting. Neoadjuvant treatment was limited 
here to a maximum of six cycles previous to surgery, while in the study by Grosso et al. 
[194] patients received a median number of 10 cycles in the advanced setting. Late 
responses are often observed with trabectedin [170], and this fact could account for the 
differences in response rate. In the present study, 16 of 21 patients with stable disease 
had tumour shrinkage of 7%-25% (data not shown). Some of these patients could have 
achieved response if treated for a longer period of time. Tumour shrinkage is usually 
preceded by a change in tumour density, which is not picked up by RECIST criteria. 
Patients in this series were not prospectively evaluated by functional imaging or CHOI
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criteria, but based on the few available data it is very likely that these tools would have 
better described the activity of this drug in this disease. Future studies will have to 
incorporate these procedures to properly assess response, especially in these tumour 
types [195].
Trabectedin was generally well tolerated and showed manageable toxicity when 
administered to ML patients as neoadjuvant chemotherapy. Common adverse reactions 
(nausea/vomiting, fatigue, neutropenia and transient transaminases increases) were 
those usually associated to trabectedin in patients with STS [170, 196-198] or other 
tumour types [193],[199]. In general, these events were transient, decreased in 
frequency over cycles, were not cumulative, had no relevant clinical consequences in 
most patients and were manageable by appropriate dose modifications or administration 
delays. These findings support that trabectedin 1.5 mg/m2 given as a 24-h i.v. infusion 
every 3 weeks is a therapeutic option with significant efficacy and minimal toxicity in 
the neoadjuvant setting of patients with ML.
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Demographic and baseline characteristics (n = 29).
Characteristic n %
Gender
Male 16 5
5
Female 13 4
5
Age (years)
Median 47
Range 2
3 -
75
ECOG PS
0 2 3 7
9
1 6 2
1
Tumour variant3
Myxoid 16 5
5
Myxoid/round cell 12 4
1
Primary tumour site
Upper extremity 2 7
Lower extremity 2 3 7
9
Trunk/abdominal wall 3 1
0
Other l b 3
Tumour stage
I 2 7
II 1 3
III 2 5 8
6
Unknown 1 3
Size of the largest tumour
<5 cm 1 3
5-10  cm 10 3
5
>10 cm 17 5
9
Unknown 1 3
No. of sites
Median 1
Range 1-2
c
More frequent sites of disease at baselined
Thigh 14 4
8
Gluteus 3 1
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0
Leg 3 1
0
Popliteal fossa 3 1
0
Previous anticancer therapy
Surgery
All types 2 9 1
0
0
Surgery other than 
diagnostic/exploratory
Marginal excision 2 7
Wide excision 3 1
0
Compartment resection 2 7
Other l e 3
Radiotherapy
External radiotherapy l f 3
TABLE 7: Data shown are no. o f  patients (%) except for ‘age’ and ‘no. o f  sites’ (median and range). The median  
time from initial diagnosis to trabectedin treatment was 1.1 months (range, 0 .3 -2  31.5m g/m 2 m g/m 2 
months) and the median time from histological analysis to trabectedin treatment was 1.1 months (range, 
0.3-31.1 months).
«*a One patient with non-myxoid liposarcoma (not included in the analysis o f  efficacy).
Corpus cavemosum bulb.
«*c Three patients had metastatic disease at baseline (hepatic, pelvic and lymph nodes metastases) not 
reported at study entry. These cases were declared protocol deviations and, therefore, they were not 
included in the primary analysis o f  efficacy. Upon evaluation for the secondary efficacy end point, all three 
had stable disease according to RECIST.
Other less frequent sites included arm, pelvis and trunk (n = 2 patients each), and mesenterium, liver and 
lymph node (n=  1 patient each).
Right leg amputation.
60 Gy in the right thigh after surgery (compartment resection).
ECOG PS, Eastern Cooperative Oncology Group performance status. [200]
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n95%
Binomial exact estim ator (Cl)
pCRper central 
pathology (primary 
efficacy end point) 3 13%  (3 -3 4 % )
Tumor regression by 
central pathology 
review
Very Good 2 9%  (1 -2 8 % )
Good 10 44%  (23 -6 6 % )
Low 7 30%  (13 -5 3 % )
Objective response 
per RECIST 
(secondary efficacy 
end point) 7 4%  (1 0 -4 4 % )
n %
PR 1 24
SD 21 72
NE 1 3
T A B L E  7: Pathological response according to RECIST after trabectedin neoadjuvant therapy [200]
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1 .6 .5  T o lera b ility .
The toxicity profile encountered in the phase II trials was similar to the results observed 
in the phase I studies evaluating the 2 4-hour continuous infusion of trabectedin at the 
recommended dose. Myelosuppression and hepatic toxicity were the most frequently 
observed adverse events (Table 8). Despite neutropenia grade 3-4 in 33%—61% of 
patients, there was a low incidence of febrile neutropenia (6%-7%), quite different from 
other agents as doxorubicin (up to 19%) [201]or ifosfamide regimens (up to 39%). [201, 
202]. Thrombocytopenia and anemia grade 3-4 was seen in 9%-22 % of pretreated 
patients, but not in first line therapy.
Liver toxicity was frequent, but not cumulative and rapidly reversible. Transaminase
elevation at more than five times the normal range was described in 20% to 57% of
pretreated and 30% of the nonpretreated patients. This toxicity could be improved by
dexamethasone premedication. In xenografts models, the hepatotoxicity induced by
trabectedin was markedly reduced or avoided after administration of metabolism
modulators such as dexamethasone or beta-naphtoflavone 24 h before trabectedin [203].
The authors reported no difference in antitumour efficacy and hypothesized a decreased
hepatic exposure to trabectedin, perhaps by regulation of hepatic metabolism [204]. In
the clinic dexamethasone premedication was retrospectively analyzed by Grosso and
colleagues[184]. Twenty-three patients treated with trabectedin 1.0 to 1.65 as a three-
hour or 2 4-hour continuous infusion every 21 days did not receive premedication
whereas 31 patients received dexamethasone 4 mg per os bid 24 hours before therapy.
The incidence of grade 3-4 transaminitis was reduced from 70% to 3% of patients by
the dexamethasone premedication. The incidence of neutropenia and thrombocytopenia
was also less important at 10% and 0% instead of 39% and 35%, respectively. The
antitumour activity was similar between the two groups and comparable to the ones
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reported in other phase II trials. The overall response rate was 9% and the median 
progression-free survival was 2.6 months.
The analysis of four treatment-related deaths in the European phase II study [180] 
revealed a statistical correlation between these severe toxicities and liver dysfunction. 
The influence of patient characteristics and pathophysiological variables was analyzed 
in 69 patients treated in phase II studies [205]. The incidence of severe toxicity was 
significantly (p = 0.02) greater for patients with any baseline liver function test 
exceeding the upper limit of the normal range. Thus the administration of the full dose 
of trabectedin at 1.5 mg/m2 requires normal alkaline phosphatase and transaminase 
levels, checked before each cycle, and the dose should be reduced to 1.2 in case of 
abnormal bilirubin level, and more than 2.5 increase of transaminase or alkalin 
phosphatase above the normal range.
Other frequent toxicities included nausea, vomiting and fatigue that could be grade 3-4 
in up to 9% of patients. Elevation of creatine phosphokinase (CK) has been reported in 
2 6% of patients and a few cases of severe and fatal rhabdomyolysis have been observed 
in the phase I—II studies [175, 179, 206]. Trabectedin induced necrosis of skeletal 
muscle resulting in subsequent release of intracellular contents leading to electrolyte 
imbalance, renal failure and death. Caution should be taken when used with other 
medications known to cause muscle injury as statins. CK is the most sensitive indicator 
of muscle injury and should be < 2 .5x upper limit of normal before each treatment and 
closely monitored during therapy.
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Febrile Thromb
Transami
nitis
Astheni
Reference N Neutropenia neutrop ocytope Nausea a/fatigu
ema ma e
YovineJ Clin 26 (48%)
Oncol. 2004 P h a se  II, 54 33(61%) 4 (7%) 10(19%) ASAT 4(7%) 8 (15%)
Mar second  line 31 (57%)
1:22(53:890- ALAT
Garcia-CarbJ 9 (26%)
Clin Oncol. 
2004 Apr 
15:22(81:148
P h a se  II, 
second  line 36 12(34%) 2(6%) 6 (17%)
ASAT
7(20%)
ALAT
2 (6%) 0
Le Cesne J 35 (35.3%)
Clin Oncol. P h a se  II, 104 52 (52.5%) 9(9.1%) 18 ASAT 7(7.1%) 0
2005 Jan second  line (18.2%) 44 (44.5%)
20:23(31:576- ALAT
Garcia- 12(34%)
C arbonero J 
Clin Oncol.
P h a se  II, 
first line 36 12(33%) 0 0
ASAT 
13 (36%)
5 (14%) 4(11%)
__2005A ue_ ALAT
Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase.
Table 8: incidence, o f grade 3A toxicities in phase II trial [178]
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1.6.6 C om b in ation s
Combination treatments with doxorubicin [207] rinotecan, [208] and paclitaxel [209] 
were evaluated in preclinical studies showing synergistic effects against sarcomas. 
Trabectedin was combined with doxorubicin, egylated liposomal [210] doxorubicin, 
paclitaxel, and capecitabine in phase I studies involving patients with solid tumours. 
The DLT were essentially myelosuppression and hepatotoxicity.
In sarcomas a phase I study combining doxorubicin and trabectedin reported that the 
maximum tolerated dose was 60 and 1.1 respectively. Preliminary pharmacokinetics of 
both agents were not significantly modified by the combination. Because of severe 
neutropenia at the first dose level, granulocyte colony-stimulating factor had to be 
added subsequently. The dose limiting toxicities were neutropenia and thrombopenia. 
Dose reduction was required in 51% of patients for trabectedin and 27% for 
doxorubicin. Among the 41 treated patients, five achieved a partial remission and 34 
had a disease stabilization that lasted more than six months in 15 patients.
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1.6 .7  R esista n ce  to  T rab ected in
Only a few cell lines have been described that show specific resistance to trabectedin. 
The resistance to trabectedin of the colorectal carcinoma ER5 cell line (derived from the 
HCT116 cells) is associated with a loss of heterozygosity at 13q33, where the gene 
encoding for XPG is located. Sequential analysis of the XPG gene showed an insertion 
of adenine at codon 240, which resulted in a stop codon at position 243 [148,211] . 
Another mechanism associated with trabectedin's resistance has been described in 
human surgically resected chondrosarcoma cells (CS-1; [212]). Alteration in the 
cytoskeleton architecture, mainly related to modified types I and IV collagen 
expression, has been shown in this cell line model [139]. In a different study, 
continuous exposure for 10 months to increasing doses of trabectedin (up to 800 
nmol/L) generated highly resistant, overexpressing P-gp ovarian cancer cells [213].
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1.7  S u m m ary
A sarcoma is a type of cancer that develops from certain tissues, like bone or muscle. 
There are 2 main types of sarcoma: bone sarcomas and soft tissue sarcomas. Soft tissue 
sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood 
vessels, or deep skin tissues. They can be found in any part of the body. There are about 
50 different types of soft tissue sarcomas and most of them develop in the arms or legs. 
They can also be found in the trunk, head and neck area, internal organs, and the area in 
back of the abdominal cavity (known as the retroperitoneum). Liposarcomas are 
malignant tumors of fat tissue. They can develop anywhere in the body, but they most 
often develop in the thigh, behind the knee, and inside the back of the abdomen. They 
occur mostly in adults between 50 and 65 years old.
After a sarcoma is found and staged, the cancer care team will recommend one or 
several treatment options. In choosing a treatment plan, factors to consider include the 
type, location, and stage of the cancer, as well as your overall physical health. The main 
types of treatment for soft tissue sarcoma are: Surgery, Radiation, Chemotherapy, 
Targeted therapy.
Interest in marine natural products has allowed the discovery of new drugs and 
trabectedin (ET-743, Yondelis), derived from the marine tunicate Ecteinascidia 
turbinata, was approved for clinical use in 2007. It binds to the DNA minor groove 
leading to interferences with the intracellular transcription pathways and DNA-repair 
proteins. In vitro antitumor activity was demonstrated against various cancer cell lines 
and soft tissue sarcoma cell lines. In phase I studies tumor responses were observed also 
in different soft tissue sarcoma subtypes.
The most common toxicities were myelosuppression and transient elevation of liver
function tests, which could be reduced by dexamethasone premedication. The
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efficacy of trabectedin was established in three phase II studies where it was 
administered at 1.5 mg/m2 as a 24 h intravenous infusion repeated every three weeks, in 
previously treated patients. The objective response rate was 3.7%-8.3% and the tumor 
control rate (which included complete response, partial response and stable disease) was 
obtained in half of patients for a median overall survival reaching 12 months. In non­
pretreated patients the overall response rate was 17%. Twenty-four percent of patients 
were without progression at six months. The median overall survival was almost 16 
months with 72% surviving at one year. Predictive factors of response are being 
explored to identify patients who are most likely to respond to trabectedin.
Trabectedin was associated with antitumour activity in a series of patients with myxoid 
liposarcoma. The noted patterns of tumour response were such that tissue density 
changes occurred before tumour shrinkage in several patients. In some patients, tissue- 
density changes only were seen. Long-lasting tumour control was noted in responsive 
patients. The surprising finding on the sensitivity of liposarcoma tumors carrying a 
specific translocation involving a negative regulator of adipogenesis prompted us to 
investigate the mechanism of action of trabectedin related to this differentiation 
pathway.
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Chapter 2:
MATERIALS AND METHODS
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2 .1 A n im als
Female athymic NCr-nu/nu mice, seven weeks old, were obtained from Harlan 
Laboratories (Udine, Italy). They were maintained under specific pathogen-free 
conditions, housed in individually ventilated cages and handled using aseptic 
procedures. Procedures involving animals and their care were conducted in conformity 
with the institutional guidelines that are in compliance with national (Legislative 
Decree 116 of Jan. 27, 1992 Authorisation n.l69/94-A issued Dec. 19, 1994 by Ministry 
of Health) and international laws and policies (EEC Council Directive 86/609, OJ L 
358. 1, December 12, 1987; Standards for the Care and Use of Laboratory Animals, 
United States National Research Council, Statement of Compliance A502 3-01, 
November 6, 1998).
2.2 In vivo studies
For the antitumour activity studies, female athymic nude mice were engrafted s.c. with 
ML014, ML015 (with type II fusion transcript) or ML004, ML006 (with type III fusion 
transcript) myxoid liposarcoma fragments as previously described by Roberta Frapolli 
[48]. The growing tumour masses were measured with a Vernier caliper, and the tumour 
weights (1mm3 = lmg) were calculated with the formula: length x (width)2/2 . When 
tumour weight reached about 400 mg, mice were randomized and treatment started. 
Trabectedin (generously provided by PharmaMar, Madrid, Spain) was given i.v. at the 
dose of 0.15 mg/kg, every seven days for three times (q7dx3). Each group comprised at 
least seven mice. Drug efficacy was calculated as T/C%, where T and C are the mean 
tumour weights of treated and control groups, respectively. The treatment was 
considered active when T/C<42 %.
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For the molecular analysis mice bearing type II (ML015, ML014) or type III (ML006 or 
ML004) xenografts were treated with trabectedin starting when tumour weight reached 
about 600 mg. Mice where sacrificed at different time points after the first and the third 
dose of trabectedin. Tumours were immediately collected and snap-frozen on dry-ice or 
processed for chromatin immunoprecipitation as described later.
2.3 Chromatin Immunoprecipitation
Tumours and cells were washed in phosphate-buffered saline and incubated for 10 min 
with 1% formaldehyde (VWR International PBI srl, Milan, Italy). After quenching the 
reaction with glycine 0.1 M, the cross-linked material was sonicated into chromatin 
fragments of an average length of 500/800 bp. Chromatin was kept at -80°C. 
Immunoprecipitations were performed with ProtG Sepharose (KPL, Milan, Italy).
Italy and 5pg of the indicated antibodies: CHOP (F-168, Santa Cruz, California, USA), 
FUS (Bethyl, Milan, Italy) and anti-Flag antibody (F742 5, Sigma Aldrich, St Louis, 
USA). The chromatin solution was precleared by adding ProtG-Sepharose for 2 hours 
at 4 °C and was aliquoted and incubated with the antibodies overnight at 4°C on a 
rotating wheel. ProtG-Sepharose was blocked with 1 pg/1 salmon sperm (Sigma 
Aldrich) and 10 pg/1 bovine serum albumin overnight at 4 °C and then incubated with 
chromatin and antibody for 2 hours. Immunoprecipitated material was washed 9 times 
with wash buffer. Cross-links were reversed by incubating samples for 5 h at 65 °C in 
200mM NaCl and lOpg of RNase A to eliminate RNA. Recovered material was treated 
with proteinase K, extracted with phenol/chloroform/isoamyl alcohol (25:24:1), and 
precipitated. The immunoprecipitated DNAs were resusepended in 50pl of H 20 and 
analyzed by quantitative Real Time PCR. Values are reported as fold enrichment over 
the control antibody-Flag (Sigma Aldrich). Satellite sequences repeated at multiple
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positions in the genome were used as a control for unspecific precipitation and as a 
loading control.
2.4 Western Blot analysis
Western blot analysis ensures separation of proteins according to size using sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS/PAGE), transferring them to 
membrane electrophoretically and then using specific antibodies to detect the protein of 
interest.
2.4.1 Protein extraction preparation.
Total proteins were extracted from cultured cells by a lysis method. Basically cell 
cultures were washed twice with ice-cold PBS and then detached with a disposable 
scraper. The suspension was then centrifuged at 1500 rpm for 5 minutes and, after 
centrifugation, the pellet was resuspended in an amount of lysis buffer dependent on the 
size of cell pellet.
Lysis buffer composition: 50 mM Tris-HCl pH=8 , 150 mM NaCl, 10% glycerol, 1 mM 
MgCL, 1 mM EGTA, lOOmM NaF, 1% Triton X-100 in the presence of IX protease 
cocktail inhibitor (Sigma) and 5mM NasVCL as phosphatase inhibitor.
Lysates were incubated on ice for 30 minutes. Insoluble cellular debris were pelleted at 
13000 x g for 10 min at 4°C and the total protein present in the supernatant was 
recovered and placed in a fresh Eppendorf tube (1.5 ml). An aliquot (2 ul) was used to 
determine protein concentration.
To evaluate xenograft proteins, explanted tumours were immediately snap-frozen. 
Frozen specimens were diluted into a volume of ice-cold lysis buffer in a fixed ratio (1 
ml / 10 mg) and homogenized with a ultra-turrax homogenizer. Lysates were incubated 
on ice for 30 minutes and then centrifuged at 13000 rpm (17000 x g) for 10 min at 4°C
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at least two times to pellet insoluble cellular debris. 2 ul of clear lysates were used to 
measure protein concentration.
2.4.2 Calibration Curve Preparation.
For the calibration curve, a solution of bovine serum albumin (BSA) (1 mg/ml) was 
prepared dissolving powdered BSA (Sigma) in water. For each calibration point, 800 ul 
of distilled water were mixed with 200 ul of BioRad Protein Assay (BioRad) and 
transferred into disposable cuvettes (PBI International). Calibration points of the 
standard curve were generated by adding 2 ,4,6, 8 and 10 ul of BSA solution to 1 ml of 
Biorad diluted solution. The absorbance at 595 nm was measured in the 
spectrophotometer. The absorbance value corresponding to the blank sample was 
subtracted from the values obtained from the BSA-containing samples. The calibration 
curve obtained in such a way allows extrapolation of the exact absorbance value 
corresponding to 1 ug of proteins present in the solution.
2.4.3 Determination of protein concentration
The concentration of proteins in the samples was determined by mixing 2 ul of protein 
cellular extract to the Biorad diluted solution as done for the calibration curve points. 
Protein sample concentration was found by interpolating the registered absorbance with 
the standard curve.
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2 .4 .4  S D S -P A G E
Depending on the protein under evaluation, 30 ug to lOOug of protein total extract were 
mixed with a corresponding volume of 5X SDS loading buffer (50 mM tris-HCl 
pH=6.8; 2 % SDS, 0.1% Bromophenol Blue, 10% Glycerol, 5% p-Mercapto Ethanol) 
and the mixture was boiled for 5 min. Samples were loaded onto a 5% stacking gel and 
a range of 6-15% separating gel:
Stacking and running gel were prepared shortly before pouring. Ammonium persulphate 
catalyses polymerization and TEMED accelerates the reaction and so these two reagents 
were added last.
Proteins were resolved on a minigel apparatus (BioRad) and run for approximately 2 h 
at 100V in IX TGE running buffer (2 5 mM Tris base, 2 5OmMglycine, 0.1% SDS): 
Electrophoresis progress was followed using pre-stained molecular weight markers (11- 
170 Kda, Page Ruler Prestained Protein Ladder, FERMENTAS)
2 .4.5 Protein Transfer and Detection.
The separated proteins were transferred onto nitro-cellulose (Whatman Protran, Milan, 
Italy) or PVDF membrane (Millipore, Billerica, MA, USA), depending from the protein 
under evaluation, using BioRad Mini transfer blot equipment in IX Transfer Buffer 
(50mM Tris base, 10 OmM glycine, 0.01% SDS, 2 0% methanol). A constant power of 
60V was applied for 2 hours.
Filters were stained with Ponceau red solution (Sigma) to check for sample loading and 
transfer. Nitrocellulose Membrane was saturated with 5% non-fat dried milk dissolved 
in TBS-T (Tris-HCl pH=8 lOmM, NaCl 150mM, Tween 200.05%) for 1 hour to block
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non-specific binding. Identical effect was obtained by air-drying PVDF membrane for 1 
hour after washing it in pure methanol.
All the following procedures were carried out on a shaker. Blots were exposed for 2 h 
at room temperature or O/N at 4°C to the desired primary antibodies diluted at the 
appropriate concentration in 5% non-fat dry milk in TBS-T or in TBS-T 5% BSA.
After incubation, blots were washed twice for 15 minutes with TBS-T 0.1% and 
incubated with the appropriate horseradish-peroxidase linked anti-mouse, anti-goat or 
anti-rabbit IgG secondary antibody (SantaCruz) for 2 h using 1:3000 dilutions in 5% 
non-fat dry milk in TBS-T to reveal primary antibody binding. Blots were washed for at 
least 1 hour in TBS-T, and detection was performed with an enhanced 
chemiluminescent detection system (ECL, Amersham-Life Science). Immunoblotting 
was carried out with the following antibodies: CHOP (F-168, Santa Cruz 
Biotechnology), PTX3 (kindly gave by Lavena P), PPARyl,2 (E-100, Santa Cruz 
Biotechnology), C/EBPa (C-18, Santa Cruz Biotechnology), P-Actin (C-4 Santa Cruz 
Biotechnology). Binding was detected using peroxidise labelled secondary antibodies 
and visualised using a chemiluminescence kit (Amersham, Milan, Italy).
2 .4.6 Isolation of Nuclear Proteins
At least lOxlO6 402 -91 cells were scraped from the culture plates into ice-cold PBS and 
harvested by centrifugation at 1500 rpm for 5 min; the pellet was resuspended in 400 uL 
of ice-cold buffer A (250 mM sucrose; 20 mM Hepes-KOH pH 7.5; 10 mM KC1; 
15OmM MgC12 ; 1 mM Na-EDTA; 1 mM Na-EGTA; 1 mM DTT; 0.1 mM PMSF) and 
homogenized 40 times on ice with a Teflon potter to break open the cell membranes. 
The homogenate was centrifuged twice at 750 x g for 10 minutes at 4°C to precipitate 
nuclei. The supernatants was centrifuged at 10,000 x g for 15 min at 4°C to discard the
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pellet (residual nuclei and mitochondria-containing fraction), and supernatant (cytosolic 
fraction) was collected. Protein expression in nuclei and soluble fraction was 
determined as previously described.
2 .5 Transcripts analysis 
2 .5.1 RNA extraction and purification
The SV total RNA isolation kit (Promega, Madison, Wi, USA) was used for isolating 
total RNA. With this method is possible to isolate pure RNA from relatively few cells 
(106) in a limited time (1-2 hours). The cells are lysed in a guanidine thiocyanate 
containing solution which maintains the integrity of RNA while disrupting cells and 
dissolving cell components. RNA was then prepared following manufacture’s 
instructions. The purified RNA is then eluted with a small volume of water (generally 
50 microliters). 2 ul of this solution were used to determine RNA concentration by 
using NANO-DROP technology. Samples were stored at -20°C until required for use. 
Alternatively an aliquot (2 ul) of this solution was diluted in sterile water to a final 
volume of 100 ul, and the RNA concentration was measured spectrophotometrically 
following the formula RNA (mg/ml) = OD2 60 nm x 40 x dilution factor. The amount of 
RNA is calculated considering that a solution of 40 ug of RNA in one ml would give an 
absorbance reading of 1.0 at 260 nm. The 260/280 assorbance ratio must be between 1.8 
and 2 .0 for a sample of reasonable purity. RNA was eluted by adding 100 ul of pre­
heated nuclease-free water on the filter followed by centrifugation at maximum speed 
for 30 sec. Total RNA’s concentration was measured as previously indicated.
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2 .5.2 Semi-quantitative RT-PCR
cDNA Archive KIT (Applied Biosystems, Monze, Italy) was used to perform 
retrotranscription reaction: A range from 200 ng to 1 ug of total RNA is retrotranscribed 
to cDNA using random hexamers.
Optimal primer pairs spanning splice junctions were chosen, using PRIMER-3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgi) and their specificity was 
verified by the generation of single amplicon bands of in the PCR products and melting 
curves. Primers pairs to detect specific FUS-CHOP isoforms were as previously 
described (CCR VOL7, pg 3977-3987 December 2001).
The reaction protocol was: 16°C for 30 min - 42 °C for 30 min -  85° for 5 min and 
final hold at 4°. cDNA reaction products were stored at -20°C until the PCR steps. 
Primers used to detect FUS-CHOP 
FUS-CHOP forward TGGCTATGAACCCAGAGGTC
FUS-CHOP reverse TCCCGAAGGAGAAAGGCAAT ”
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2 .5.3 Real Time PCR Procedures
PCR reaction master mix was made in a final volume of 20 ul following the 
manufacturers instructions.
Regarding SYBR green technology, all couples of primers were designed on the basis 
of the sequence reported in the Ensembl database. “Primer3” software freely available 
online was used to design the best set of primers to be used for each gene. Synthesis of 
oligonucleotides used as primers was performed by Sigma.
5 to 10 ng of cDNA were used for each reaction of Real-time PCR. GoTaq qPCR 
Master Mix (Promega) was used with the following primers to perform reactions on 
7900HT Sequence Detection System (Applied Biosystems).
Differences in gene expression were determined by real time RT-PCR (ABI-7900, 
Applied Biosystems) using Syber Green (Applied Biosystems). The reactions were 
subjected to initial incubation at 95°C for lOmin followed by 45 cycles of 95°C for 
15sec and 60°C for lm in\ Raw data were generated with SDS Relative Quantification 
Software (Applied Biosystems). To calculate the relative expression of each mRNA, we 
used the 2 'DDCT method to average the threshold cycle (CT) values for three replicates. 
Chip analysis was determined by RT-PCR (ABI-7900, Applied Biosystems) using 
Syber Green ( Applied Biosystem). The reactions were subjected to initial incubation at 
95°C for 10 min followed by 40 cycles of 95°C for 30sec, 66°C for 30 sec and 72 °C for 
30 sec. Raw data were generated with SDS Relative Quantification Software (Applied 
Biosystems). Values are reported as fold enrichment calculated with the following 
formula:2 AACtx - 2 AACtb, where ACtx = Ct input -  Ct sample and ACtb = Ct input - 
Ct control Ab (Flag).
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Primers used for gene expression analysis
PTX3 forward CCCACCAAATTCAGGGGAACT
PTX3 reverse CCACTACCCCTTCCAGGACT
FN-1 forward CTTCGCTTCACACAAGTCCA
FN-1 reverse GCAGCGAACAAAAGAGATGC
£ /EBP beta forward GAGGAGGCGGAGGTTTCAG 
C/EBP beta reverse GTGGGAGTTTACGGGAGGAA
.C/EBP alfa forward GCCTGCCGGGTATAAAAGCTC 
C/EBP alfa reverse GACTCCATGGGGGAGTTAGAG
Primers used for ChIP analysis
PTX3 forward CCCACCAAATTCAGGGGAACT
PTX3 reverse GCATTGCTGGAGAGACGCAAA
FN-1 forward CTTCGCTTCACACAAGTCCA
FN-1 reverse GCAGCGAACAAAAGAGATGC
CHOP forward CCTAGCGAGAGGGAGCGACG
CHOP reverse GTCTCTGACCTCGGGAGCGCC
IL-8 forward AGGTTTGCCCTGAGGGGATG
IL-8 reverse GCTTGTG TGCTCTGCTGTCTC
SAT11 (Control satellite sequences were amplified using) forward
CAATTATCCCTTCGGGGAATCGG
SAT 11 reverse GGCGACCAATAGCCAAAAAAGTGAG
TSP-1 forward CCC A AC A A ATT C AGGGGA ATT
TSP-1 reverse GCATTGCTAGAGAGACGCAAA
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2 .6 Acquisition of tumour biopsies
The biopsy was obtained from a 43 year-old patient with recurrent myxoid liposarcoma 
started as round cell in a lower extremity and eventually with metastasis to soft tissue, 
pleura, mediastinum, heart. Trabectedin was used as front-line therapy at a dose of 1.1 
mg/kg via portable infusion device (pump baxter) infusion for 24 h.
The biopsy was obtained before and 24 h after the first cycle.The patient has continued 
for 11 cycles of infusions in total, resulting in a response both in size and density of the 
tissue already after 3 cycles of treatment.
2 .7 Cells and culture conditions
The myxoid liposarcoma cell line 402 -91 was kindly supplied by Aman P. (36). 402 - 
91 cell were grown in adhesion in RPMI-1640 medium (Biowest S.A.S., Nuaille, 
France) supplemented with 10% fetal bovine serum (Sigma Aldrich, St.Louis, USA), 
1% L-glutamine 2 mmol/L, Bio west) and 1% penicillin-streptomycin lO.OOOpg/ml, 
(Biowest). Cells were maintained at 37°C in a humidified 5% carbon dioxide 
atmosphere in T2 5 and T75 cm2 tissue flasks (IWAKI, Bibby Sterilin, Staffordshire, 
UK).
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2.8 ELISA assay
Enzyme linked immunosorbent assay (ELISA) is a quantitative technique to evaluate 
the presence of a specific antigen into a solution. From a standard curve, made from a 
series of known concentrations of our target, is possible to find the unknown 
concentration of the specific antigen present in the sample of interest. Human TSP-1 in 
the plasma of tumor-bearing mice was detected with Quantikine Immunoassay (R&D 
System). Sensitivity of the assay was 0.355 ng/mL. Each sample was analyzed in 
duplicate. This analysis was routinely performed in the “ Thrombosis Unit” at the Mario 
Negri Bergamo. Proteins from treated and untreated samples were given to be analyzed.
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Chapter 3 
AIM
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Previously, It was identified the effects of trabectedin on the promoters of several 
cancer related genes and has shown that this compound affects transcription factor 
regulation [143, 214]. Based on our data, we hypothesize that the selective anti-tumour 
activity of trabectedin against ML is due to its ability to counteract the oncogenic 
activity of the FUS-CHOP fusion protein generated by the tumour specific translocation 
[60].
During my PhD, I wanted to build up on discoveries made in previous studies and to 
characterize the mechanism of the selective activity of trabectedin in ML. The aim of 
my project was to study the effect of trabectedin on ML at the molecular level in vitro 
and at the cellular level in vivo. My project will involve:
1) Molecular characterization of the interference of trabectedin with transcription 
alteration caused by the expression of the FUS-CHOP fusion gene.
2) Determination of differential sensitivity of FUS-CHOP variants to trabectedin 
and its clinical significance.
3) Identification of the effect of trabectedin on angiogenesis pathway in vivo and in 
vitro.
My goal was to gain further insight into the mechanism of action of trabectedin at the 
molecular level, particularly focusing on the effect of trabectedin treatment on the 
expression of genes induced by FUS-CHOP fusion.
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Chapter 4: 
RESULTS
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4.1 Detection of FUS-CHOP fusion transcripts in 402 -91cell line.
Previous studies have demonstrated that trabectedin has a selective antitumour activity 
against ML with the translocation t (12;16) (ql3; p i 1) with a FUS-CHOP fusion gene 
of type 1 and 2 [59]. According to this, as cell line model, I have chosen the 402-91 cell 
line carrying type 1 FUS-CHOP fusion. To determine the presence of the chimera type
1 .1 have done RT-PCR using primers able to discriminate between the different FUS- 
CHOP isoforms.
RT-PCR analysis with FUS-CHOP Type I isoform specific primers identified a single 
band at 526 bp confirming the presence of the expected fusion transcript in 402-91 cells 
(Figure 25).
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5 0 0  b p
F igure 25: RT-PCR analysis o f  FUS-CHOP fusion m RNA. Lane 1- 1Kb D N A  Ladder, Lane 2 - RT-PCR analysis o f  
FUS-CHOP mRNA in 402 -91 cells. Note the presence o f  a single band at 526 bp identifying the presence o f  type I 
isoform in 402 -91 cell line.
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4.1 .1  E ffec t o f  tra b ected in  trea tm en t on  tran scr ip tion  reg u la tio n  o f  F U S -C H O P
To delineate the mechanistic basis of how trabectedin treatment could affect the 
expression of genes, such as PTX3 and FN-1, already known to be specifically 
regulated by FUS-CHOP, I have performed RT-PCR analysis on 402 -91 cells.
402 -91 cells were treated with trabectedin at 5nM, corresponding to the IC50 value or 
with lOnM (=2 xIC50) trabectedin. After trabectedin was washed out, cells were 
incubated in drug free medium and were allowed to recover for 6 or 24 hours. mRNA 
levels of PTX3 and FN-1 extracted from cells treated with 1 hour of trabectedin and a 
recovery of 6 hours were decreased significantly when compared to untreated cells. The 
mRNA levels of PTX3 and FN-1 were further reduced in cells treated and recovered for 
24 hours compared to untreated controls (figure 26).
The expression of PTX3 and FN-1 were significantly altered even with the low dose of 
trabectedin. Thus, the decrease in expression of FUS-CHOP targets is likely due to the 
trabectedin effect on the transcription factor activity of the fusion protein indicating that 
the chimera could be directly affected by the compound.
To determine whether trabectedin could cause a decrease in the protein level of FUS- 
CHOP, I have analyzed the expression of the chimera by western blot before and after 
the treatment. To detect FUS-CHOP protein I have used an antibody against CHOP 
because there is no antibody specifically against the chimera. However, it is possible to 
discriminate the oncogenic fusion from the endogenous CHOP protein by difference in 
their molecular weights.
First, I have confirmed that the chimera protein was present exclusively in the nuclear 
fraction as previously shown (Figure 27). This corroborates the fact that FUS-CHOP 
protein could be acting as a transcription factor.
By western blot analysis I found that the protein levels of FUS-CHOP fusion in the
nucleus were the same treated and untreated 402 -91 cells. There was no change in the
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cellular localization of the chimera with trabectedin treatment. These results showed 
that trabectedin affects were not due to a decrease of the protein level or localization of 
FUS-CHOP fusion.
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Figure 26: Real time RT-PCR analysis performed in 402 -91 at different times o f  recovery in drug free medium after 
lh  o f  treatment with different doses trabectedin (0, 5 and 10 nM). Data were analysed by the AACT method and 
expressed as fold changes (arbitrary unit) compared to their untreated control set as 1. Data are the mean o f  three 
independent experiments performed in triplicates. Bars, +/- SD.
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Figure 27: Western blot analysis o f  402 -91 cell lines carrying the translocation t(12 ; 16) (q l3 ; p i 1), using anti- 
CHOP antibodies (GAD 153). The cells were harvested after 1 hour after treatment with the indicated concentrations 
o f  trabectedin. Yb was used as nuclear loading marker for data normalization.
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4.1.2 Trabectedin’s effect is related to changes in the transcription modulation 
mediated by FUS-CHOP.
Despite the significant effect of trabectedin on the transcription of FUS-CHOP target 
genes, we have not seen a significant change in the FUS-CHOP protein levels with 
treatment, suggesting that trabectedin might be affecting the DNA binding activity of 
FUS-CHOP. In order to verify this hypothesis, I have looked closely at the DNA 
binding activity of FUS-CHOP.
To determine whether the transcriptional changes were primary events, I monitored 
binding of FUS-CHOP to promoters of PTX3 and FN-1 by ChlP. For this purpose, I 
have established ChlP protocol and optimized the conditions to obtain reliable and 
consistent results with selected antibodies. Since, no antibody was available to 
recognize the specific chimera, FUS-CHOP was precipitated by the anti-FUS and anti- 
CHOP antibodies separately. It was therefore essential to monitor both CHOP and FUS 
in the same ChlP. A satellite 11 (Satl 1) sequence that is repeated multiple times in the 
genome was used as a control for non-specific precipitation along with an irrelevant 
anti-Flag as a negative control. To test if FUS-CHOP was binding to the PTX3 and FN- 
1 promoters, I initially performed ChlP assays using untreated 402-91 cell line. I have 
evaluated both promoters in quantitative RT-PCR. Values were reported as a fold 
enrichment over a Flag antibody as a negative control.
I next checked whether the trabectedin treatment affected the chimera fate. I ’ve 
performed three independent experiments in triplicates each time. 402 -91 cells were 
treated with 2 nM of trabectedin for 1 hour and recovered in drug free medium for 6 
hours and 24 hours. I saw that the enrichments were significantly reduced in the treated 
cells already after 1 hour of treatment (figure 28). With respect to the anti-Flag control
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antibody, binding was significantly affected on all the promoters tested even after 6 
hours and 24 hours of recovery (figure 29, figure 30).
Most importantly, I observed that trabectedin caused detachment of the chimera from 
PTX3 and FN-1 promoters already after lh of treatment confirming that trabectedin 
removes FUS-CHOP from its target promoters at low dose. I concluded that trabectedin 
induces the removal of the chimera from promoters, which in turn alters their 
expression and their functionality.
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Figure 28: ChlP from untreated cells and treated with 2 nM o f  trabectedin for 1 hour with, a-CHOP, a-FU S, a-Flag  
(Ctl) antibodies. Two promoters were evaluated in quantitative Real Time PCR analysis. Values are reported as fold  
enrichment over anti-Flag antibody.
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F igure 29: ChlPs analysis o f  402 -91 cells untreated and treated with 2 nM o f  trabectedin at 6 hours o f  recovery in a 
drug free medium after 1 hour o f  treatment. The promoters region o f  PTX3 and FN-1 were amplified. Values were 
measured as fold enrichment over a Flag control antibody in quantitative RT-PCR analysis.
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Figure 30: 402 -91 cells were treated with 2 nM o f  trabectedin and recovered for 24 hours in drug free medium and 
chromatin analyzed by ChlP with the indicated antibodies. PTX3 and FN-1 promoters bound by FUS-CHOP, were 
evaluated in quantitative RTPCR analysis. Values are reported as fold enrichment over the control Flag antibody.
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4 .1 .3  T rab ected in  rescu es th e  a d ip o cy te  d ifferen tia tion  b lo ck  in vitro.
Previous studies have identified a number of transcription factors involved in adipocyte 
differentiation. These include PPARy and members of the C/EBP family of 
transcription factors. These transcription factors are expressed as a cascade in which 
C/EBPp and C/EBP5, during the first stages of the adipocyte differentiation program, 
induce the expression of C/EBPa and PPARy, the master regulator of adipogenesis [69, 
70, 79].
Based on ChlP results, I have performed RT-PCR with mRNA extracted from 402 -91 
cells untreated or treated with trabectedin. I have found that C/EBPp was present in 
untreated cells and increased after the treatment with trabectedin (figure 31). On the 
other hand, C/EBPa was not present in untreated cells and was rapidly induced at the 
mRNA level by trabectedin (figure 31). Taken together these data indicate that 
trabectedin could be involved in the induction of adipocyte differentation in 402 -91 
cells, by removing the chimera from its own target genes.
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Figure 31: ML 402 -91 cells were treated with 5 and 10 nM o f  trabectedin. Cells were washed after 1 hour o f  
treatment and allowed to recover for 6 and 24 hours. Data are the mean +/- SD (Bars) o f  three replicates for real time 
RT-PCR and 1. Only fold changes <0.5 or >2 were considered to be statistically significant.
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4 .2  T ra b ected in  b lock s F U S -C H O P  b in d in g  in vivo.
In parallel, I planned to set up the methodology to perform the ChlP assay in samples 
from xenografts in mice, to see how trabectedin treatment affects the tumour 
composition in an in vivo xenograft model. The technical challenge was to optimize the 
ChlP protocol for its application in ex vivo ML tissue, which was not done before.
Microscopically ML is made of uniform round-oval primitive non-lipogenic cells and 
variable numbers of uni-multivacuolated lipoblasts intermixed with a well-developed 
plexiform capillary network and embedded in a myxoid matrix composed of hyaluronic 
acid. Depending on the proportion of the cellular component to the stroma and the 
prevalence of immature and mature cellular features ML is divided into a usual or pure 
subtype, and a round cell or cellular (RC) subtype. Usual ML is the most differentiated 
form and shows low cellularity, evidence of lipoblast differentiation and a conspicuous 
vascular network while the RC subtype presents the opposite extreme of the 
differentiation gamut, and shows high cellularity made up of primitive non-lipogenic 
cells, little or no intervening myxoid stroma and a capillary vascular pattern that is not 
easy to visualize. Diagnosis of the RC subtype requires >5% hypercellular area [48].
For these particular features that characterize ML, the main problem for performing 
ChlP on xenografts was to obtain sufficient number of cells necessary for 
immunoprecipition -5 millions cells at least. I discovered that incubation of ML 
xenografts with collagenase enzyme allowed efficient dissociation of the tumour single 
cells. From lOOmg of ML xenografts I obtained 50 millions cells after collagenase 
digestion, the protocol that I have set up is described in more details in paragraph 4.4 
(Methodological design for Chromatin Immunoprecipitation to increase the fold 
enrichment).
120
These cells were used for Chip assay. I monitored the binding of FUS-CHOP to its 
promoters by ChlP with anti-CHOP, anti-FUS, and control antibody: an irrelevant anti- 
Flag.
The xenografts used after were previously established and characterized by Roberta 
Frapolli [48], ML004 and ML006 carrying FUS-CHOP type III. Both of the xenografts 
were treated with trabectedin at 0.15 mg/kg every 7 days for 3 times. Samples were 
collected 24 hours after the first dose, 24 hours after the third dose and 15 days without 
trabectedin. I have evaluated promoters of well-known FUS-CHOP chimera target 
genes (PTX3, FN-1, IL-8, CHOP) in quantitative RT-PCR. Values were reported as 
fold enrichment over a Flag antibody as a negative control.
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F igure 32 : ChlPs were performed on xenograft model M L004 with the indicated antibodies and analyzed by RT- 
PCR with the appropiate primers. Values are reported as fold enrichment calculated with the fo llow ing formula:2 
AACtx - 2 AACtb, where ACtx = Ct input -  Ct sample and ACtb = Ct input - Ct control Ab (Flag). Samples were 
collected 24 hours after the first dose, 24 hours after the third dose and 15 days without trabectedin. I have evaluated 
selected promoters such as PTX3, FN-1, IL-8, CHOP in quantitative RT-PCR. Values were reported as fold  
enrichment over a Flag antibody as a negative control.
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Figure 32 (continued): ChlPs were performed with the indicated antibodies and analyzed by RT-PCR with the 
appropiate primers. Values are reported as fold enrichment calculated with the follow ing formula:2 AACtx - 2 AACtb, 
where ACtx = Ct input -  Ct sample and ACtb = Ct input - Ct control Ab (Flag).
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Figure 33: ChlPs were performed on xenograft model M L006 with the indicated antibodies and analyzed by RT- 
PCR with the appropiate primers. Values are reported as fold enrichment calculated with the follow ing formula:2 
AACtx - 2 AACtb, where ACtx = Ct input -  Ct sample and ACtb = Ct input - Ct control Ab (Flag). The xenografts 
were treated with trabectedin at 0.15 m g/kg every 7 days for 3 times.
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Figure 33 (continued) : ChlPs were performed with the indicated antibodies and analyzed by RT-PCR with the 
appropiate primers. Values are reported as fold enrichment calculated with the follow ing formula:2 AACtx - 2 AACtb, 
where ACtx = Ct input -  Ct sample and ACtb = Ct input - Ct control Ab (Flag).
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I saw that the enrichments were significantly reduced in the trabectedin treated 
xenografts already 24 hours after the first dose (figure 32 , figure 33). With respect to 
the anti-Flag control antibody, binding was significantly affected on all the promoters 
tested even after 24 hours after the third dose.
Even at 24h after the first dose of Trabectedin, detachment of the chimera from all the 
promoters was seen confirming that it removes FUS-CHOP from its target promoters in 
xenograft ex vivo ML tissue, like previously observed in ML cell line.
15 days after treatment, FUS-CHOP was again bound to its own target genes, like 
before treatment. These data indicate that trabectedin induces the removal of the 
chimera from promoters which in turn alters their expression and their functionality 
even on xenografts samples, suggesting that this is the mechanism of action of 
trabectedin in vivo as well as in vitro.
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4.2 .1 Expansion of previous findings on the effects of trabectedin on FUS-CHOP 
target in new ML xenografts carrying FUS-CHOP type II.
Previously I described that Trabectedin caused detachment of the chimera from the 
promoters of target genes selected already 24 hours after the first dose of treatment 
confirming that it removes FUS-CHOP from its target promoters in xenograft in vivo 
ML tissue carrying FUS-CHOP TYPE III, as previously observed in ML cell line.
To further investigate if this mechanism was present in others ML, ChlP assay was 
performed in xenografts carrying FUS-CHOP type II; ML014, M1015 established and 
characterized by Roberta Frapolli [48]. Both xenografts were treated with trabectedin at 
0.15 mg/kg every 7 days for 3 times. Samples were collected 24 hours after the first 
dose, 24 hours after the third dose and 15 days without trabectedin. All FUS-CHOP 
gene targets promoters selected were evaluated in quantitative RT-PCR. Values were 
reported as fold enrichment over anti-flag antibody as a negative control.
In both xenografts ML014 and ML015 (figure 34, figure 35), the enrichments were 
significantly reduced in the trabectedin treated xenografts already 24 hours after the first 
dose. With respect to the anti-Flag control antibody, binding was significantly affected 
on all the promoters tested even after 24 hours after the third dose.
Trabectedin caused the detachment of FUS-CHOP from PTX3, FN-1, IL-8, CHOP, 
promoters already 24h after the first dose of treatment and 15 days after treatment, FUS- 
CHOP was again bound to its own target genes, like previously observed in xenograft 
ML carrying type III. These data indicate that trabectedin induces the removal of the 
chimera from promoters which in turn alters their expression and their functionality 
even on xenograft samples characterized by FUS-CHOP type II, suggesting that this 
could be the mechanism of action of trabectedin in vivo in all the types of chimera.
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Figure 3 4 :  ChlPs were performed on xenograft model MLO14 with the indicated antibodies and analyzed by RT- 
PCR with the appropiate primers. Samples were collected 24 hours after the first dose, 24 hours after the third dose 
and 15 days without trabectedin. A ll FUS-CHOP gene targets promoters selected were evaluated in quantitative RT- 
PCR. Values were reported as fold enrichment over anti-flag antibody as a negative control.
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Figure 34 (co n tin u ed ): ChlPs were performed with the indicated antibodies and analyzed by RT-PCR with the 
appropiate primers. Values are reported as fold enrichment calculated with the follow ing formula:2 AACtx - 2 AACtb, 
where ACtx = Ct input -  Ct sample and ACtb = Ct input - Ct control Ab (Flag).
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Figure 35: ChlPs were performed on xenograft model M L015 with the indicated antibodies and analyzed by RT- 
PCR with the appropiate primers. Values are reported as fold enrichment calculated with the follow ing formula:2 
AACtx - 2 AACtb, where ACtx =  Ct input -  Ct sample and ACtb = Ct input - Ct control Ab (Flag). Sam ples were 
collected 24 hours after the first dose, 24 hours after the third dose and 15 days without trabectedin.
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Figure 35 (c o n tin u ed ): ChlPs were performed on xenograft m odel M L0015 with the indicated antibodies and 
analyzed by RT-PCR with the appropiate primers. Values are reported as fold enrichment calculated with the 
following formula:2 AACtx - 2 AACtb, where ACtx = Ct input -  Ct sample and ACtb = Ct input - Ct control Ab  
(Flag).
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4 .2 .2  D o x o ru b ic in  d oes n o t cau se th e d eta ch m en t o f  F U S -C H O P  from  on its ow n
ta rg et gen es.
To verify the specificity of the drug for FUS-CHOP, we treated ML004 with 
doxorubicin 8mg/kg and samples were collected 24 hours after the first dose (figure 36). 
After doxorubicin treatment FUS-CHOP was still attached to PTX3 promoter 
confirming that the detachment of the chimera is only caused by trabectedin but not by 
other drugs.
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F igure 36: The promoter region o f  PTX3 and FN-1 were amplified. Values were measured as fold enrichment over a 
Flag control antibody in quantitative RT-PCR analysis. M L004 was treated with doxorubicin 8m g/kg and samples 
were collected 24 hours after the first dose.
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4.2  .3 A n ti-tu m o u r a ctiv ity  o f  trab ected in  in  x en o g ra ft m od els.
The antitumour activity of trabectedin was evaluated in ML004, ML015 xenografts 
after i.v. administration of 0.15 mg/kg, every seven days for three times. Treatments 
started when tumour burden reached 400-500 mg (late stage tumours) giving us the 
possibility to observe both tumour growth or tumour regression. As shown in figure 37, 
trabectedin was only marginally active in ML004 xenograft being able to slightly 
reduce tumour growth rate but without reaching a significant value of T/C (52 .2 % on 
day 156).
On the contrary ML015 was very sensitive to the treatment (T/C 17.4% on day 175): in 
this xenograft model trabectedin was able to induce a 50% tumour regression, followed 
by a long lasting tumour growth arrest (figure 37). Histological analyses were 
performed before and 15 days after the end of treatment. H&E sections of the xenograft 
ML004 before and after treatment did not show any morphologic change (figure 38) 
whereas H&E sections of the ML015 xenograft showed a partial response in post­
treatment samples characterized by a consistent cellular depletion (figure 39).
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Figure 37: Antitumour activity o f  trabectedin in M L004 xenograft and M L015 (B): tumour bearing m ice were 
treated with trabectedin 0.15 m g/kg i.v., q7dx3. Treatment started when the mean tumour weight w as about 500 mg. 
Bars, ±SEM.
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Figure 38: Bars, ±SEM . H em atoxylin/eosin sections o f  or M L004 xenografts w ere perform ed before and 15 days 
after the end o f  treatm ent.
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Figure 39:B ars, ±SEM . Hem atoxylin/eosin sections o f  M L015 xenografts were perform ed before and 15 days after 
the end o f  treatm ent.
136
4.2 .4 Trabectedin induces adipocytic differentiation in ML type II but not in ML  
type III.
Histological analysis revealed that trabectedin causes a consistent cellular depletion, and 
a progression toward a differentiated lipoblast phenotype in type II ML, while it 
induced a minor effect in type III ML (figure 38, 39). Previously, it was shown that 
trabectedin induced a transcription program of adipogenesis, specifically in 402 -91 
cells, by inducing the master genes of this process such as C/EBP(3 and C/EBPa. In 
order to confirm that trabectedin treatment induced the adipogenesis in vivo, we 
examined the expression levels of the proteins responsible for normal adipogenesis such 
as C/EBPa and PPARy2 using in vivo xenograft before and after the treatment. As 
shown in figure 40 and 41, before the treatment only PPARy 1 was expressed in both 
ML015 (type II) and ML004 (type III). Before treatment, none of the tumours expressed 
C/EBPa or PPARy2 . After trabectedin treatment, PPARy2 and C/EBPa expression was 
induced only in ML015 (type II) but not in ML004 (type III). Interestingly, we found 
that in ML004 (type III), after treatment there was no increase in the protein expression 
compared to the control (figure 41). Taken together, these results suggest that 
trabectedin induces maturation /adipocyte differentiation in ML carrying FUS-CHOP 
type II but not in ML carrying FUS-CHOP type III.
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Figure 40: A nalysis o f  adipocytic m arkers in xenograft m odel M L015: Trabectedin was adm inistered i.v. at the 
dose o f  0.15 m g/kg every seven days for three tim es (q7dx3). W estern blot analysis was done on sam ples 24 hours 
after the first and the third dose and 15 days w ithout trabectedin w ith antibodies against P P A R y l,2 (A) and C /EB Pa 
(B ).
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Figura 41: Analysis o f  adipocytic m arkers in xenograft m odel M L004: Trabectedin was adm inistered i.v. at the 
dose o f  0.15 m g/kg every seven days for three tim es (q7dx3). W estern Blot analysis o f  PPARy (A) and C /E B P a (B).
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4.2 .5 Trabectedin decrease the expression of CHOP and PTX3 in ML015 (type II) 
but not in ML004 (type III) xenograft tumours.
To determine if trabectedin could cause a decrease in the protein levels of PTX3 and 
CHOP which are FUS-CHOP target genes, I have analyzed the expression of both 
proteins by westemblot in ML004 and ML015 xenograft models.
Tumours were collected 24 hours after the first dose, 24 hours after the third dose, and 
15 days without trabectedin. As shown in figures 42 and 43, before trabectedin 
treatment CHOP and PTX3 were expressed in both tumours. 15 days after trabectedin 
CHOP and PTX3 protein levels were dramatically decreased compared to the control in 
the ML015, but not ML004 xenograft tumour. This is consistent with the histological 
analysis. However these data were in contrast to the ChIP data showing that trabectedin 
had the same ability to display FUS-CHOP types from the selected gene targets in both 
ML004 and ML015.
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Figure 42 : A nalysis o f  FU S-CH O P target after trabectedin treatm ent in X enograft m odels M L015. X enografts were 
treated w ith trabectedin at 0.15 m g/kg every 7 days for 3 tim es. Sam ples were collected 24 hours after the first dose, 
2 4 hours after the third dose and 15 days w ithout trabectedin. Total extracts were subjected to W estern Blot with 
CHO P and PTX3. A ntibody against actin was used as a loading control.
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Figure 43: A nalysis o f  FU S-CHO P target after trabectedin treatm ent in X enograft m odels M L004. X enografts were 
treated w ith trabectedin 0.15 m g/kg every 7 days for 3 tim es. Sam ples were collected 24 hours after the first dose, 2 4 
hours after the third dose and 15 days w ithout trabectedin. Total extracts were subjected to W estern Blot w ith C H O P 
and PTX3. Antibody against actin was used as a loading contro
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4.2 .6 Trabectedin inhibition is more prolonged in tumours with FUS-CHOP type 
II than FUS-CHOP type III.
Trabectedin showed a minimal activity against ML004 xenograft (best T/C 52 %, day 
156) as confirmed by the histological analysis that showed no regression. Nevertheless, 
trabectedin showed a very good antitumour activity against ML015 xenograft (best T/C 
17%, day 175) and the histological analysis showed a partial regression with reduction 
of cell number and vasculature. To further investigate the difference response we 
performed ChIP to assess if there was a difference in the kinetics of rebinding of FUS- 
CHOP between ML type II and type III. Xenografts were treated with trabectedin at 
0.15mg/kg every 7 days for three times. Samples were collected 72 hours after the first 
dose, 72 hours after the third dose, 12 0 hours after the third dose and after 7 days 
without trabectedin. PTX3 and FN-1 promoters were evaluated in RT-PCR as fold 
enrichment over anti-flag antibody. ChIP analysis performed on ML004 revealed that 
72 hours after treatment, FUS-CHOP Type III was attached to selected targets whereas 
FUS-CHOP Type II remained unbound but was rebound to the promoters 120 hours 
after the third dose (figure 44, 45). These results suggest that the greater sensitivity of 
type II than of type III myxoid liposarcoma xenografts could be related to a more 
prolonged drug-induced detachment of the chimera FUS-CHOP from its target genes.
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Figure 44: In M L004 xenograft model, samples were collected 72 hours after the first dose, 72 hours after the third 
dose, 120 hours after the third dose and after 7 days without trabectedin. FUS-CHOP type III is binding its own target 
genes 72 hours after the 1st and the 3rd dose o f  trabectedin.
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F igure 45: In M L015 xenograft model samples were collected 72 hours after the first dose, 72 hours after the third 
dose, 12 0 hours after the third dose and after 7 days without trabectedin. FUS-CHOP type II is detached from its own 
target genes, 72 hours after the 1st and the 3rd dose o f  trabectedin.
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4.2  .7  B iop sies o f  m eta sta tic  lesion s o f  M y x o id  L ip osarcom a.
In one case of ML we obtained tumour biopsies both before and after trabectedin 
treatment. Figure 46 shows that after trabectedin the enrichment of CHOP in clearly 
decreased. When we received the samples we were not informed that the tumour did not 
express the most frequent FUS-CHOP chimera, but instead the least frequent EWS- 
CHOP chimera. Therefore we have used the antibodies against FUS and CHOP like the 
experiments conducted in xenograft biopsies. The decrease in CHOP enrichment 
indicates that trabectedin was able to remove the oncoprotein from DNA in clinical 
tumour biopsy taken 24h after treatment with trabectedin at the dose of 1.1.
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Figure 46: ChIP analysis from human biospies. PTX3 and FN-1 promoters were evaluated in RT-PCR as a fold  
enrichment over anti-flag antibody.
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4.3 To investigate the effects of trabectedin on factors that modulate angiogenesis 
response of myxoid liposarcoma.
As already outlined in the background section, the formation of the tumour vasculature 
is critical for the growth of ML. An experimental study has recently demonstrated that 
dormancy of liposarcomas is associated with impaired angiogenesis, whereas the 
acquisition of the angiogenic ability (“angiogenic switch”) triggers the passage from 
dormant, poorly vascularized lesions to rapidly growing malignant liposarcomas [215, 
216]. Preliminary observations indicate that following treatment with trabectedin 
tumours appear less vascularized. It is therefore plausible that inhibition of angiogenesis 
might contribute to the antineoplastic activity of trabectedin on ML. The aim of the 
current task is to investigate whether the changes in gene expression caused by 
trabectedin might modify the host / tumour interaction by inhibiting the angiogenic 
potential of tumour cells.
To verify whether trabectedin is an indirect inhibitor of angiogenesis, the effect of 
trabectedin on the production of angiogenesis regulatory factors was investigated in 
vitro [217, 218].
402 -91 cells were exposed to trabectedin and the production of angiogenic factors and 
endogenous inhibitors of angiogenesis, were measured by real time PCR and ELISA 
analysis of supernatant.
Initially we checked the expression of mRNA levels of VEGF using the 402 -91 cell 
line. Previously, the IC50 concentrations for trabectedin on 402 -91 cells were 
calculated as 5nM. 402 -91 cells were treated with InM, 5nM (=IC50) and lOnM (=2 
xIC50) of trabectedin. mRNA levels of VEGF extracted from cells treated with 1 hour 
of trabectedin were increased significantly when compared to untreated cells (figure
147
47). However, ELISA analysis showed that VEGF protein levels in untreated cells, at 
detection limit, were not changed by trabectedin (figure 47).
Based on previous studies showing that thrombospondin-1 (TSP-1) is a critical regulator 
of angiogenesis in sarcoma [131], we wanted to investigate if the production of TSP-1 
was affected by trabectedin treatment in 402 -91 cell line. 402 -91 cells were treated with 
InM, 5nM and lOnM of trabectedin for 1 hour. Trabectedin caused a significant 
increase in the production of TSP-1, as increase in mRNA and protein secreted in the 
supernatant and measured by ELISA (figure 48). Taken together these data show that 
trabectedin does affect the expression of specific angiogenesesis regulatory genes, 
hence potentially impairing tumour cells’ ability to stimulate angiogenesis.
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F igure 47: E ffect o f  trabectedin o f  V EG F by 402-91 cells, in vitro. Production o f  VEGF in 402-91 cells exposed to 
the indicated concentration o f  trabectedin was analyzed by real time PCR (A) or ELISA assay o f  the conditioned  
media (B). Data, expressed as fold increase, are the mean and SE o f  values from 3 independent assays. *p <0.05  
compared to controls (AN O V A follow ed by Dunnett’s multiple comparison test).
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Figure 48: E ffect o f  trabectedin o f  TSP-1 by 402-91 cells, in vitro. Production o f  TSP-1 in 402-91 cells exposed to 
the indicated concentration o f  trabectedin was analyzed by real time PCR (A) or ELISA assay o f  the conditioned 
media (B). Data, expressed as fold increase, are the mean and SE o f  values from 3 independent assays. *p <0.05  
compared to controls (AN O V A follow ed by Dunnett’s multiple comparison test).
149
To better understand the effects of trabectedin we wanted to investigate if TSP-1 protein 
levels were affected by trabectedin also in vivo.
ML004 Xenograft (carrying FUS-CHOP TYPE III) and ML015 (carrying type II) were 
characterized by R. Frapolli and treated with 0.15mg/kg of trabectedin.
TSP-1 plasma levels were detected by an ELISA that recognizes only human (hence 
tumour-derived) TSP-1. Plasma was collected 24 hours after the first dose (Tl) and 24 
hours after the third dose (T2) and 15 days without trabectedin (recovery). In 
trabectedin-sensitive ML015, TSP-1 protein levels were increased already 24 hours 
after the first dose; in the ML004 model, less responsive to trabectedin, TSP-1 protein 
levels were induced after the third dose of trabectedin (figure 49).
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Figure 49: In vivo stimulation o f  TSP-1 production by trabectedin in ML xenografts. M ice bearing the responsive 
M L015 or the poorly responsive M L004 tumors, were treated with trabectedin (0.15 mg/kg, every 7 days for 3 times) 
and for each mouse, plasma samples were collected before, 24h after the first or 24h after the third administration o f  
trabectedin. Human TSP-1 protein was measured by ELISA. Symbols refer to each mouse. *p<0.05 compared to 
control, vehicle-treated m ice (AN O V A follow ed by Dunnett’s multiple comparison test).
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4.3.1 C/EBP p but not FUS-CHOP binds to the TSP-1 promoter in xenograft 
model ML015 and ML004.
Previous studies have shown that TSP-1 can be upregulated by C/EPB p which binds to 
a TGGCGCAAG consensus site at the TSP-1 promoter [219]. C/EPB p, which is the 
preferred dimerization partner of CHOP, and also binds to FUS-CHOP, has been 
reported as an important regulator of IL6 expression. It was shown, by RNA 
interference experiments, the presence of C/EPB p is essential for expression of IL6 in 
FUS-CHOP carrying cells. By ChIP analysis, it was demonstrated that C/EBP p binds 
the IL6 promoter in FUS-CHOP carrying cells but found no direct binding of FUS- 
CHOP to this promoter. Thus, the effect of FUS-CHOP on IL6 expression must be 
indirect, possibly by interaction with C/EPB p [220].
Based on this study, I used ChIP to investigate if FUS-CHOP or C/EBPp bound directly 
to the TSP-1 promoter in ML xenograft model. ML0015 xenograft tumour was treated 
with trabectedin at 0.15 mg/kg and samples were collected 24 hours after the first dose. 
RNA polymerase II was used as control to validate if the regulation of TSP-1 was 
affected by trabectedin treatment. I have analyzed the selected promoters PTX3 and 
TSP-1 and values were reported as fold enrichment over a Flag antibody as a negative 
control.
Interestingly, the results showed that FUS-CHOP type II did not bind to TSP-1 
promoters where as C/EBP p did in the control, but after trabectedin treatment C/EBP p 
was detached from the promoter (figure 50).
To further investigate if the effect of trabectedin on TSP-1 was similar to the effect 
observed on FUS-CHOP target genes, I performed ChIP on ML015 and ML004 
xenograft models. Both of the xenografts were treated with trabectedin at 0.15 mg/kg 
every 7 days for 3 times. Samples were collected 24 hours after the first dose, 24 hours
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after the third dose and 15 days without trabectedin. TSP-1 promoter was evaluated in 
quantitative RT-PCR. Values were reported as fold enrichment over a Flag antibody as 
a negative control.
I found that trabectedin displaces C/EBP p from TSP-1 promoter in both ML xenografts 
but after 15 days without trabectedin, C/EBP p was partially rebinding just on TSP-1 
promoter in ML004 (51, 52). Taken together, these data not only highlight roles of 
trabectedin in the transcription regulatory pathway but also underline that in this context 
C/EBP p could interact with FUS-CHOP repressing the expression of TSP-1.
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Figura 50: ChlPs were performed on xenograft m odel M L015 with the indicated antibodies and analyzed by RT- 
PCR with the appropiate primers. Values are reported as fold enrichment calculated with the follow ing formula:2 
AACtx - 2 AACtb, where ACtx = Ct input -  Ct sample and ACtb = Ct input - Ct control Ab (Flag).
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F igure 51: M L015. The promoter region o f  TSP-1 amplified. Values were measured as fold enrichment over a Flag 
control antibody in quantitative RT-PCR analysis.
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Figure 52 :. M L004. The promoter region o f  TSP-1 was amplified. Values were measured as fold enrichment over a 
Flag control antibody in quantitative RT-PCR analysis.
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4.4 Methodological design for Chromatin Immunoprecipitation to increase the fold 
enrichment.
Chromatin immunoprecipitation (ChIP) is a powerful and widely applied technique for 
detecting the association of individual proteins with specific genomic regions in vivo. In 
this technique, live cells are treated with formaldehyde to generate protein-protein and 
protein-DNA cross-links between molecules in close proximity on the chromatin 
template in vivo. A whole-cell extract is prepared, and the cross-linked chromatin is 
sheared by sonication to reduce average DNA fragment size to 500 bp. The resulting 
materials are immunoprecipitated with an antibody against a desired protein, modified 
(e.g., acetylated, phosphorylated, methylated) peptide, or epitope (in situations where 
the protein of interest is epitope-tagged). DNA sequences that directly or indirectly 
cross-link with a given protein (or modified variant) are selectively enriched in the 
immunoprecipitated sample [221 ].
The amounts of specific genomic regions in control and immunoprecipitated samples 
are determined individually by quantitative PCR. The fold enrichment of certain 
chromosomal sequences (e.g., presumed binding sites) relative to other chromosomal 
sequences (e.g., presumed nonbinding sites) provides quantitative information about the 
relative level of association of a given protein with different genomic regions. Protein 
association with specific genomic regions can be performed under a variety of 
conditions (e.g., environmental change, cell-cycle status) and/or in wild-type versus 
mutant strains. In addition, ChIP can be combined with microarray technology to 
identify the location of specific proteins on a genome-wide basis [221,222].
Previously I have described how to perform ChIP on xenograft samples using 
collagenase enzyme to dissociate the tumour. In order to improve the 
immunoprecipitation, I have developed an improved ChIP assay by replacing the 
traditionally used random fragmentation step with a site-specific enzyme digestion 
using micrococcal enzyme. Instead of dissociating the tumours to obtain a sufficient 
number of live single cells, I extracted the chromatin directly from the tissue
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homogenized by Turax with lysis buffer. After the chromatin was measured by 
nanodrop, 50 pig was used to be digested by micrococcal enzyme.
The site-specific ChIP allows the immunoprecipitation and enrichment of DNA 
fragments containing only Transcription Factor Binding Sites. Chromatin is isolated by 
micrococcal digestion from whole tissue, generating oligonucleosomes which can 
range in size from mononucleosomes up to 10- to 12 -mers, depending on the time of 
digestion. The concentration of micrococcal can also be manipulated for the final 
concentration of chromatin fragments [223].
Figure 53 shows the difference in the two protocols, with sonicated material having an 
average length of 1.3 kb and careful titration of MNase I-reducing chromatin to single 
nucleosomes. Binding of FUS-CHOP to two representative CCAAT promoters—PTX3 
was monitored by ChIP analysis with a set of core promoter primers. In addition, I 
compared the efficiency of FUS-CHOP binding in ChlPs performed with sonicated and 
MNase I-treated chromatins. The 5 to 8-fold enrichment with anti-CHOP and anti-FUS 
over a control FLAG antibody routinely scored with sonicated material was 
dramatically enhanced to 2 0 to 30-fold in MNase I ChlPs (figure 54).
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Figura 53: Comparison o f  chromatin preparations: on the left sonicated, on the right M Nase I digested.
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Figura 54: Comparison o f  ChIP assays performed with sonicated and with M Nase I-digested chromatin; enrichment 
over a negative control antibody (Flag) was measured by quantitative real-time PCR.
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Myxoid liposarcoma (ML) accounts for one-third of liposarcomas and represents a 
morphologic continuum encompassing myxoid and myoxid/round cell variants, the 
latter characterized by an extent of round cell component >5% [1], [48]. Molecular 
hallmark of ML is the presence of FUS-CHOP fusion protein. CHOP belongs to and is a 
negative regulator of the large CAAT/enhancer binding protein family (C/EBP) whose 
a, p and 5 members are master regulator of adipogenesis [54, 224-226]. Clinical studies 
indicate a peculiar sensitivity of these tumours to the natural marine compound 
trabectedin. In particular it was shown that trabectedin displayed an objective RECIST 
response rate of 50% of advanced and previously pretreated ML patients with a median 
PFS of 17 months, with 90% of patients free of progression at 6 months. Substantial 
radiological changes in tumour density anticipated tumour shrinkage in 75% of 
responding patients and were visible in almost 80% of patients having obtained disease 
stabilization [227]. The surprising finding on the sensitivity of liposarcoma tumours 
carrying a specific translocation involving a negative regulator of adipogenesis 
prompted us to investigate the mechanism of action of trabectedin related to this 
differentiation pathway. One hypothesis was that the activity of trabectedin was related 
to the functional impairment of the FUS-CHOP oncogene.
I have investigated the molecular mechanism underlying the activity of the anticancer
drug trabectedin using 402 -91 cell line carrying type 1 FUS-CHOP fusion (fig 25) as an
in vitro model. In order to investigate the effects of trabectedin at molecular level, I
have treated 402 -91 cells with 5nM or 10 nM of ET-743 for 1 hour and recovered them
for 6 and 24 hours with a drug free medium. Initially, I have performed RTPCR to
evaluate the expression of genes specifically regulated by FUS-CHOP such as PTX3
and FN-1 after the treatment. I have shown that trabectedin was able to effect both
genes’ expression already after 1 hour (fig 28, 29) indicating that the drug could affects
FUS-CHOP interaction with the DNA. To understand if the compound removed the
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chimera from the DNA, I’ve proceeded with ChIP analysis and found that Trabectedin 
leads to a 6-10 fold enrichment reduction in 402-91 cells already after 1 hour of 
treatment. These data confirmed the action of Trabectedin directly on the oncogenic 
FUS-CHOP chimera. Previous studies [79] indicate that FUS-CHOP arise and function 
in the uncommitted cells in which FUS-CHOP prevents the development of adipocyte 
precursors interfering with PPARy and C/EBPa activities (figure 55, figure 56).
According to this, I have performed RTPCR analyzing the expression of C/EBPp and 
C/EBPa. C/EBPp is considered the early marker of the adipogenesis, and was found 
that ML is characterized by the accumulation of early adipocytic precursors. I saw that 
in untreated cells, C/EBPp was expressed but after treatment there was an increase of 4 
fold suggesting that the removal of the chimera could be crucial for the unblock of 
adipogenesis pathway. Interestingly, I found an increase of 11 fold in C/EBPa 
expression after the treatment compared to the untreated cells where the Transcription 
factor was not expressed. Taken together, this study provides evidence that trabectedin 
treatment might affect the adipogenesis in myxoid liposarcoma harbouring the chimera 
gene FUS-CHOP type I.
The data presented provide evidence for direct interference of trabectedin with DNA 
binding of oncogenic FUS-CHOP protein without affecting the chimera protein levels. 
We speculate that trabectedin binding to the DNA changes the structure of DNA and 
removes FUS-CHOP from the promoter regions of its targets, resulting in releasing the 
block of adipogenic differentiation in ML. This is shown by marked increase in the 
expression of late adipogenic markers in ML cell lines in vitro.
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differentiation. Transcriptions are expressed in cascade in w hich C/EBP8 and C/EBPp, expressed during the first 
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Figure 56: FUS-CHOP blocks the adipocyte differentiation program in mesenchymal cell progenitors by interfering with the 
PPARy and C/EBPa activities at the transcriptional level [79],
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Since the in vitro cell lines do not necessarily mimic the complexity of ML biology in 
vivo, we have developed xenograft models using tumour biopsies from patients with 
different breakpoints of FUS-CHOP chimera. The present study shows that trabectedin 
induces the displacement of FUS-CHOP chimera from the promoters of target genes in 
vivo, in human ML growing in mice. This effect was observed giving tolerable 
therapeutic doses of trabectedin, suggesting that the highly selective antitumour activity 
of trabectedin associated to the drug ability to induce adipocytic differentiation of ML is 
related to the ability of the drug to impair the transactivating function of the chimera, 
that is probably responsible for the block of differentiation. This mechanism appeared to 
be highly specific as other transcription factors were not affected (e.g. NF-YB [143]), 
and is likely to be responsible also for the striking antitumour activity of trabectedin in 
patients with ML. This is suggested by the observation made in tumour biopsies of one 
patient -who received a relative low dose of trabectedin of 1.1 corresponding to 
approximately 75% of the recommended dose-showing that the drug was able to 
displace the chimera from DNA. To our knowledge this is the first report indicating that 
a small molecule can displace an oncogenic transcription factor in vivo from its target 
DNA sequences, thus specifically modulating the transcription of genes involved in the 
pathogenesis of a neoplastic disease. Many attempts previously made to identify 
compounds that selectively block oncogenic transcription factors have failed, although 
many in vitro data have been published using many different molecules including 
nucleic acids, peptides and also small DNA binding ligands [228, 229]. For example 
some years ago our group had reported that some natural products that bound in the 
minor groove in AT rich DNA sequences such as distamycins were able to specifically 
prevent the binding of some transcription factors to DNA [127, 230-232] and similar 
data were published for other DNA minor groove binders [231]. However these in vitro 
findings were never confirmed in vivo, thus justifying some skepticisms about the
possibility to target transcription factors as a potential anticancer therapy, although it 
remained theoretically very appealing in consideration of the large number of tumours 
that are driven by an altered function of transcription factors. The reason why this 
approach was not successful is related to the fact that, in vivo, the complexity of the 
transcription regulation is much higher than in vitro, involving interactions between 
multiprotein complexes and chromatin and drug design is not feasible because the three 
dimensional structures of the complexes is not fully elucidated yet. In this respect the 
finding that trabectedin, a marine natural product that binds in the minor groove of 
DNA modifying DNA bending with some degree of sequence specificity [127], can 
specifically block the DNA binding of an oncogenic transcription factor in a specific 
manner is of great scientific interest and may stimulate the interest in setting up drug 
discovery programs aimed at identifying new compounds that are directed to the 
inhibition of transcription factors.
The high level of specificity of the observed mechanism of action of trabectedin in ML 
is highlighted by the observations that the drug-induced differentiation could be 
influenced by the breakpoint of the translocations. We found that ML type II xenografts 
were more sensitive to trabectedin than ML type III ones, these result being in keeping 
with higher probability of response in patients with type II than with type III chimera 
[227].
The histological analysis on the xenografts ML015 and ML004 showed that trabectedin 
induce a cellular component depletion and increase of mature adipoblasts in type II ML, 
while in type III ML there was not any histological response, indicating that, in our 
experimental conditions, trabectedin induces maturation in ML carrying FUS-CHOP 
type II but not in ML carrying FUS-CHOP type III (figure 38, 39). [233]
Previous studies have identified a number of transcription factors involved in adipocyte
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differentiation. These include PPARy and members of the C/EBP family of 
transcription factors [76]. Many of the components of the gene regulatory network that 
controls the differentiation of adipocytes have been elucidated in studies of cultured 
3T3-L1 preadipocytes and MEFs [74, 75]. These transcription factors are expressed as a 
cascade in which C/EBPp and C/EBP8, expressed during the first stages of the 
adipocyte differentiation program, induce the expression of C/EBPa and PPARy the 
master regulator of adipogenesis. A positive feedback loop mechanism between PPARy 
and C/EBPa enhances their activities. This transcriptional cascade finishes with the 
expression of markers of mature adipocytes such as aP2, adiponectin and adipsin [234]. 
There are two PPARy isoforms generated by alternative splicing, PPARyl and PPARy2 
, with PPARy2 being more efficient to induce terminal differentiation in vitro [79]. It 
was recently demonstrated that FUS-CHOP interferes with the PPARy2 and C/EBPa 
activities. In addition, it was shown that the regulation of the translation machinery by 
FUS-CHOP plays an important role in the blockade of adipogenesis associated to 
liposarcoma development [79]. According to this, I used Western Blot to analyze the 
expression level of C/EBPa, PPARyl and PPARy2. I found that after trabectedin 
treatment C/EBPa and PPARy2 were expressed only in ML015 carrying FUS-CHOP 
type II (figure 41, 42 ) but not in ML004 carrying FUS-CHOP type III. Taken together 
these data provide evidence that trabectedin induces adipocytic differentiation in ML 
carrying in type II FUS-CHOP but not in ML expressing type III FUS-CHOP.
The different response to trabectedin observed in type II and type III ML could be due
to a different ability of the drug to displace the binding of the chimera from target
promoters. The experiments done, however, showed that in both type II and type III
subtypes tumours after treatment with trabectedin FUS-CHOP was not bound to DNA.
Nevertheless when treatment was stopped, the kinetic of reattachment of the chimera to
DNA appeared to be different for the two subtypes, being faster for the type III than for
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type II. The longer duration of the block of FUS-CHOP might justify the different 
biological effects that were observed. It might be speculated that the larger size of type 
III chimera makes the complex of transcription factor-cofactors and DNA more stable. 
Therefore when the drug is partially cleared from the tumour after some days after 
treatment, the drug concentrations in tumour cells might be sufficient to prevent the 
binding of type II but not of type III chimera. Alternatively for some reasons the amount 
of drug bound to DNA of type II remained longer than on type III, implying that some 
differences in the DNA repair mechanisms occur.
In the last century anti-cancer therapies concentrated on natural or engineered
molecules having the capacity to target the neoplastic cells. Often these tactics do not
completely remove the tumour mass and select for resistant clones of cancer cells able
to repopulate tumour sites. A new strategy to develop therapies capable of creating a
hostile niche for neoplastic cells could be a starting-point. The possibility to contrast
cancer cells with a single molecule is obviously naive. A set of different molecules able
to target tumour cells, able to normalize the angiogenic network and to restore the
correct function of immune cells, could increase the chance of success. The
development of the tumour vasculature is crucial for the growth of ML. An
experimental study has recently demonstrated that dormancy of liposarcomas is
associated with impaired angiogenesis, whereas the acquisition of the angiogenic ability
triggers the passage from dormant, poorly vascularized lesions to rapidly growing
malignant liposarcomas [215, 216]. Preliminary observations indicate that following
treatment with trabectedin tumours appear less vascularized. It is therefore plausible that
inhibition of angiogenesis might contribute to the antineoplastic activity of trabectedin
on ML. Based on this observations I investigated whether the changes in gene
expression caused by trabectedin modifies the host tumour interaction by modulating
the angiogenic process. Initially the expression of mRNA levels of VEGF and TSP-1
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were checked using 402 -91 cell line. VEGF protein levels did not change whereas TSP- 
1 protein levels were affected. Afterwards, to forward investigate the effects of 
trabectedin, TSP-1 protein level was investigated using in vivo models. Xenograft 
samples carrying FUS-CHOP type II has shown a higher response, i.e. increase in TSP- 
1 levels, compared to xenograft samples carrying FUS-CHOP type III which has shown 
a lower response, confirming that ML type II was more sensitive to trabectedin 
compared to ML type III. This sensitivity was demonstrated even at molecular level 
using ChIP assay.
These findings, therefore, support the idea that to obtain an improved treatment effect in 
type III ML, the interval between doses should be reduced, and studies are in progress 
to test this hypothesis in preclinical ML xenograft models.
In summary I have provided evidence that trabectedin has a highly specific mode of 
action in ML, being able to displace the product of the fusion gene- that represents the 
hallmark and the pathogenetic lesion of the disease from its target promoters. The 
functional inactivation of the oncogenic chimera by trabectedin treatment leads to the 
derepression of the adipocytic differentiation. The duration of the block of the 
transactivating activity of the chimeric protein seems to be important as highlighted by 
the differences found in type II and type III ML, a finding of potential clinical 
importance to attempt different dosage-schedules of the drug according to the molecular 
characterization of the fusion gene.
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7.1 A b b rev ia tio n s
ATM ataxia-telangiectasia mutated
ATR ataxia-telangiectasia mutated and rad3-related bZIP basic leuzine zipper region
CDK cyclin dependent kinase
cDNA complementary deoxyribonucleic acid
CHK checkpoint kinase 2
C/EBP CCAAT/enhancer binding protein
CHOP C/EBP homologous protein
CT computed tomography
CR complete responde
CHOP DNA-damage-inducible transcript 3 (DDIT3,
GADDI 53)
DDLS dedifferentiated liposarcoma 
DNA deoxyribonucleic acid 
EGFP enhanced green fluorescent protein 
EGFR epidermal growth factor receptor
ECOG PS, Eastern Cooperative Oncology Group performance status.
EWS Ewing sarcoma 
FNA fine needle aspiration 
FUS fusion (TLS)
GADD153 growth arrest and damage-inducible 153 
IBMX 3-Isobutyl-I-methylxanthin 
IFN-" interferon-gamma 
IHC immunohistochemistry 
IL interleukin
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M L m yxoid  liposarcom a
MM maintenance medium
MR minor response
MRI magnetic resonance imaging
PCNA proliferating cell nuclear antigen
pCR pathologic complete response
PD progression desease
PDGFR platelet derived growth factor receptor
PFS progression free survival
PLS pleomorphic liposarcoma
PPAR peroxisome proliferator-activated receptor pRB retinoblastoma protein
PR partial response
RCLS round cell liposarcoma
RNA ribonucleic acid
RT-PCR reverse transcription-polymerase chain reaction RXR retinoid X receptor 
SCID severe combined immune deficient 8 
SD stable disease
TNF-a tumour necrosis factor alpha
TLS translocated in liposarcoma (FUS) UVB ultraviolet B
VEGFR vascular endothelial growth factor receptor WDLS well-differentiated 
liposarcoma
WHO World Health Organization
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